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ABSTRACT

Using Immune Modulators to Ameliorate Aleutian Disease in Mink

by

Kie Hoon Jung, Doctor of Philosophy
Utah State University, 2003

Major Professor: Dr. Edmund D. Brodie, Jr.
Department: Biology
Aleutian disease of mink (AD) is an immunopathological disorder induced by
persistent infection with AD virus. Many breeds of mink seem to have a high
susceptibility to AD. Interestingly, the primary feature of AD in susceptible adult mink is
a chronic, fatal immune complex-mediated glomerulonephritis comparable to that seen in
human diseases such as systemic lupus erythematosus. Because of its comparative
aspects to human diseases and the substantial economic loss to the fur industries in the
world, classical AD and the nature of the virus has been studied extensively for three
decades. Currently no therapies are available and vaccination has been a failure; the
latter exacerbated the disease.
The hypothesis tested in this research was that the treatment of AD-infected mink
with TGF-~ 1 and dehydroepiandrosterone (DHEA) inhibited or ameliorated the disease.
The hypothesis was tested by evaluating the effects of TGF-fh and epiandrostene-like
compounds on the immune response of AD-infected animals on the normal physiological
parameters of animals and by evaluating the effects of both compounds on virus loads.
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The TGF-r31 study was designed to evaluate three different doses (200, 100 and
1 ng/kg) of recombinant human TGF-r31 and one dose (500 ng/kg) of TGF-r3~inhibitor at
three different times (treated TGF-r31 2 weeks pre-, 8 hours post-, and 2 weeks post-virus
inoculation) of administration relative to virus exposure. Animals were administered
drug or placebo intravenously via the inguinal vein injection and animals were held to up
to 9 months.
For the epiandrosterone study, five mink received 16 ng/kg HE2300 once per
week, 17 animals received 16 ng/kg HE2300 three times per week, and five animals were
injected with 16 ng/kg HE2500 three times per week. In addition, 17 animals received
vehicle three times per week. All treatments were injected subcutaneously into the nape
of the neck of the mink. Animals were held to up to 8 months.
Pathological analysis of various physical, physiological and immunological
parameters in surviving mink treated with either immunomodulator (treated with TGF-r31
at 100 ng/kg and treated with HE2300 at 16 ng/kg three times per week) revealed that
these parameters were near the levels measured for normal uninfected mink. In contrast,
in untreated infected animals the measured virus pathology, and physiological and
immunological parameters were significantly different from the untreated control
animals. In a comparison of survival times, treated animals with either
immunomodulator survived almost twice as long as untreated animals. A polymerase
chain reaction (PCR) assay of lymph node tissue confirmed that AD-infected animals
treated with either immunomodulator had significantly lower levels of virus DNA than
untreated infected animals.
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These findings support the hypothesis that TGF-~ 1 and DHEA and its analogs
may afford mink protection from chronic lethal AD.
(171 pages)

VI

ACKNOWLEDGMENTS

I would especially like to thank my dissertation advisor, Dr. Dale L. Barnard, and
major professor, Dr. Edmund D. Brodie, Jr., for their guidance and for teaching me
invaluable lessons of life. I will always remember their example as hard-working and
dedicated researchers who were willing to share ideas and teach the principles behind the
experiments that were being conducted.
I would like to thank the other members of my committee, Dr. Robert W. Sidwell,
Dr. Joseph K.K. Li, Dr. Daryll B. De Wald, and Dr. John Stark, for sharing their expertise
and giving me suggestions and advice during this research project. I would like to
acknowledge the help and support of Scott Winslow, Darin Chase, Valerie Hubbard, and
Jason Roth.
Special thanks to my wife, Jung-Ae Choi, and my two daughters, Rebekah and
Michelle Jung, as well as to my mother and my father, who passed away from lung
cancer several years ago, my father- and mother-in-law and family, Ruth and Dr. Author
Moss, and Dr. Kiyo Kamikawa, for their encouragement and interest in my work, and
thanks to God.
Kie Hoon Jung

vii

CONTENTS

Page
ABSTRACT ......................................................................................................................

iii

ACKNOWLEDGMENTS

................................................................................................

vi

LIST OFT ABLES ............................................................................................................

xi

LIST OF FIGURES ........................................................................................................

xiii

CHAPTER
1. INTRODUCTION

..............................................................................................

1

Context ........................................................................................................
Literature Review .........................................................................................

1
5

Aleutian Disease of Mink ............................................................... 5
ADV Genome Structure, Protein and Replication .......................... 7
AD of Newborn Mink ................................................................... 11
Pathogenesis of Aleutian mink Disease ........................................ 12
Transforming Growth Factor-~ (TGF-~) ...................................... 14
Genomic Organization of the TGF-~ 1 Gene ................................. 15
Structure of TGF-~ ....................................................................... 16
Receptors and the Cytokine Network ........................................... 19
TGF-~ in the Immune System ...................................................... 20
References ..................................................................................................
2. AMELIORATING ALEUTIAN DISEASE IN MINK BY TREATMENT
WITH HUMAN rTGB-~ 1 ••••••••••••••...•...•..••••.•••.••.•..••.••••••...•...••.••••••...••••••••••••••.

Abstract ......................................................................................................
Introduction ................................................................................................
Materials and Methods ...............................................................................
Virus ...............................................................................................
Cell .................................................................................................
Animals ..........................................................................................
Study Design ..................................................................................
Counter-immune Electrophoresis (CEP) ......................................
Blood Urea Nitrogen (BUN) ..........................................................

27

42
42
43
47
47
47
47
48
.49
50

Vlll

Interferon Gamma (IFN-y) Assay ................................................. 50
Circulating Immune Complexes (CIC) Assay ............ .'................. 51
TGF-~ 1 ELISA Development Assay .............................................. 52
Detection of Viral DNA ................................................................ 53
Histopathology Examinations ....................................................... 54
Statistical Analysis ........................................................................ 54
Results ........................................................................................................
Survival Time .................................................................................
Body Weight .................................................................................
Specific ADV Antibody Levels ....................................................
Serum Levels of Urea Nitrogen ....................................................
Serum Gamma Interferon (IFN-y) Activity ..................................
Circulating Immune Complexes (CIC) Titers ................................
Serum Levels of TGF-~ ................................................................
Virus DNA Levels ........................................................................
Histopathological Examinations ...................................................
Discussion .................................................................................................
References .................................................................................................

55
55
55
56
56
57
57
58
59
59
60
66

3. EFFECTS OF HE 2300 AND HE 2500 ON THE OUTCOME OF
ALEUTIAN DISEASE IN MINK .................................................................... 86
Abstract .....................................................................................................
Introduction ...............................................................................................
Materials and Methods ..............................................................................

86
87
91

Animals ......................................................................................... 91
Study Design ................................................................................. 92
Cell ................................................................................................ 92
Counter Current Immunolectrophoresis ....................................... 92
Interferon-y Bioactivity Assay ...................................................... 93
Circulating Immune Complexes (CIC) Assay .............................. 93
Blood Chemistry Evaluations ...................................................... :94
Polymerase Chain Reaction Detection of Viral DNA .................. 94
Histopathological Examinations ................................................... 95
Statistical Analysis ........................................................................ 96

IX

Results .......................................................................................................

96

Effects of HE2300 and HE2500 Treatment on
Physiological and Physical Parameters of Mink
Exposed the Aleutian Disease Virus ........................................... 96
Survival Time ....................................................................... 96
Weight Gain .......................................................................... 98
Histopathological Findings .................................................. 98
Serum Levels of Ions ........................................................... 99
Serum Levels of Liver Enzymes .......................................... 99
Serum Levels of Nitrogenous Compounds ....................... .100
Effects of HE2300 and HE2500 on Viral and
Immunological Parameters in Mink Infected
with ADV .................................................................................. 101
Virus Levels ....................................................................... 101
Specific ADV Antibody Levels ......................................... 101
Circulating Immune Complexes (CIC) Titers .................... 102
Serum Gamma Interferon (IFN-y) Activity ....................... 102
Splenomegaly ..................................................................... 102
Discussion ...............................................................................................

103

HE2500 3x/wk ............................................................................ 103
HE2300 lx/wk ............................................................................ 104
HE2300 3x/wk ............................................................................ 105
References ...............................................................................................

108

4. SUMMARY AND CONCLUSIONS ............................................................. 126
ADV Immunological Response .............................................................. 126
Ameliorating Aleutian Disease in Mink by Treatment
with Human rTGF-~ 1 ••••••••••••..••.•••••••••••••••••••••.•••••••••••••••.••.•.•••••••••••••••
127
Potential Mechanisms of Inhibition ........................................... .127
Summary of Results Nine Months (266 days)
after Exposure to ADV ........................................................... .128
Conclusions: Analysis of the Mink Treated
with TGF-~ 1 .••....••.••.•..•...•.............•.....•....•...••••...•.•.•.••......•....•.
129

X

Effects of HE2300 and HE2500 on the Outcome of
Aleutian Disease in Mink ..................................................... :............... 129
Potential Mechanisms of Inhibition ............................................ 129
Summary of Results Eight Months After
Exposure to ADV ..................................................................... 130
Conclusions: Analysis of The Mink Treated with
HE2300 and HE2500 ............................................................... 131
Summary of Conclusion for Both Treatments
(TGF-~ 1 and HE2300/ 2500) ............................................................... 131
APPENDICES ................................................................................................................

132

Appendix A. Experimental Methods of Ameliorating Aleutian
Disease in Mink by Treatement with Human rTGF-~ 1....................................133
Appendix B. Tables and Figures of Ameliorating Aleutian
in Mink by Treatment with Human rTGF-~ 1 ...................................................
139
Appendix C. Tables and Figure of Effects of HE2300 and HE2500
on the Outcome of Aleutian Disease in Mink .................................................. 148
CURRICULUM VITAE .................................................................................................

154

xi
LIST OF TABLES

Table

Page

2.1

Effect of intravenous TGF-~ 1 treatment on circulating immune
complexes (CIC) in mink with Aleutian disease ................................................... 70

2.2

Detection of ADV DNA in mink treated intravenously with TGF-~ 1•.•••••..••.•••.•.• 71

2.3

Summary of histopathological findings of AD-infected
mink treated with TGF-~ 1 •..•..••.•••.••••.•...•.•....•••.••.••.••••..•.•......•........•.•..••..•.........•.••

72

Summary of results from 8 months treatment of
Aleutian mink disease with TGF-~ 1 ...•....•...•..•.••..••.•.•.•.••••.••.•...••.••.••••...........•.•.•••

73

2.4

3.1

Summary of histopathological findings of AD-infected mink
subcutaneously treated with HE2300 or HE2500 ............................................... 112

3.2

Summary of selected physical and physiological parameters
evaluated HE2300- or HE2500-treated mink infected
with ADV and surviving 8 months ..................................................................... 113

3.3

Detection of viral DNA in mesenteric lymph nodes of mink treated
subcutaneously with HE2300 or HE2500 ........................................................... 114

3.4

Summary of selected viral, serological and immunological
parameters evaluated in HE2300- or HE2500-treated mink
infected with ADV and surviving 8 months ...................................................... .115

A.1

Study Design for TGF-~ 1 treatment of ADV-infected mink ............................... 133

B.1

Effect of TGF-~ 1 treatment on survival time of mink
with Aleutian disease ..........................................................................................

139

B.2

Effect of intravenous TGF-~ 1 treatment on body weights
of mink with Aleutian disease .............................................................................. 140

B.3

Effect of intravenous TGF-~ 1 treatment on the anti-ADV
antibody titers of mink with Aleutian disease ..................................................... 141

B.4

Effect of intravenous TGF-~ 1 treatment on blood urea nitrogen
(BUN) levels in mink with Aleutian disease ...................................................... 142

xii
B.5

Effect of intravenous TGF-~ 1 treatment on serum interferon
gamma (IFN-y) levels in mink with Aleutian disease .......................... .'............... 143

B.6

Effect of intravenous TGF-~ 1 treatment on average
of serum TGF-~ 1 levels in mink .......................................................................... 144

B.7

Effect of intravenous TGF-~ 1 treatment on
serum TGF-~ 1 levels in mink ............................................................................... 145

C.1

Study Design for DHEA treatment of ADV-infected mink ................................. 148

C.2

Effects of subcutaneous HE2500 and HE2300 treatment on
survival time of ADV-infected mink .................................................................. 149

C.3

Effects of subcutaneous HE2500 and HE2300 treatment
on serum ion levels in ADV-infected mink ......................................................... 150

C.4

Effects of subcutaneous HE2500 and HE2300 treatment on
serum liver enzyme levels of ADV-infected mink ............................................. 151

C.5

Effects of subcutaneous HE2500 and HE2300 treatment on serum
levels of blood urea nitrogen and creatinine in ADV-infected mink .................. 152

xiii
LIST OF FIGURES

1.1

An illustration of the postmortem lesions of AD on mink. ................................... .41

2.1

An illustration of the visible effects of AD on mink ............................................. 74

2.2

Effect of intravenous TGF-~ 1 treatment on survival time
of mink with Aleutian disease ................................................................................ 75

2.3

Effect of intravenous TGF-~ 1 treatment on body weights
of mink with Aleutian disease ................................................................................ 77

2.4

Effect of TGF-~ 1 treatment on the anti-ADV antibody titers in mink ................... 79

2.5

Effect of intravenous TGF-~ 1 treatment on blood urea nitrogen
(BUN) levels in mink with Aleutian disease ......................................................... 81

2.6

Effect of intravenous TGF-~ 1 treatment on serum interfere
on gamma (IFN-y) levels in mink with Aleutian disease ....................................... 83

2.7

Effect of intravenous TGF-~ 1 treatment on serum TGF-~ 1 levels in mink ........... 85

3.1

Effects of subcutaneous administration of HE2300 and HE2500
treatment on survival time (Kaplan-Meier analysis)
of ADV-infected mink .........................................................................................

116

3.2

Effect of subcutaneous HE2500 and HE2300 treatment on
weight gain of ADV infected mink ...................................................................... 117

3.3

Effects of subcutaneous HE2500 and HE2300 treatment
on serum ion levels in ADV-infected mink ......................................................... 119

3.4

Effects of subcutaneous HE2500 and HE2300 treatment
on serum liver enzyme levels of ADV-infected mink ......................................... 120

3 .5

Effects of subcutaneous HE2500 and HE2300 treatment
on serum levels of blood urea nitrogen (A) and
creatinine (B) in ADV-infected mink .................................................................. 121

3.6

Effect of subcutaneous HE2500 and HE2300 treatment on the
anti-ADV antibody titers in mink serum taken after 8 months ............................ 122

XIV

3.7

Effects of subcutaneous HE2500 and HE2300 treatment
on detectable immune complexes in mink
serum taken after 8 months .................................................................................. 123

3.8

Effects of subcutaneous HE2300 and HE2500 treatment
on serum interferon-y activity of mink exposed to
Aleutian disease virus (taken after 8 months) ...................................................... 124

3.9

Effects of subcutaneous HE2500 and HE2300 treatment
on spleen weight of ADV infected mink ............................................................. 125

A.1

These pictures depict mink farm .......................................................................... 134

A.2

These figures show blood collection method ....................................................... 135

A.3

These pictures show TGF-~ 1 injection time interval ........................................... 136

A.4

These figures show TGF-~ 1 injection method ..................................................... 137

A.5

These figures depict CEP assay .......................................................................... 138

B.1

Detection of ADV DNA in mink treated with TGF-~ 1 ........................................

C.1

Detection of ADV DNA in mink treated with HE2300 and HE2500 .................. 153

147

CHAPTERl
INTRODUCTION

Context

Aleutian disease (AD) is an immunopathological disorder of mink induced by
persistent infection with AD virus (ADV), a naturally occurring infection caused by a
virus from the Parvoviridae family (Porter et al., 1980). The chronic infection often leads
to immune complex disease and is marked by a progressive renal failure. It is
characterized by a hypergammaglobulinemia, a large fraction of which consists of
antibody complexed with non-neutralizable virus. Pathological findings include
mesangial proliferative glomerulonephritis and severe interstitial nephritis comparable to
that seen in human diseases such as systemic lupus erythematosus (Bloom et al., 1994).
AD often leads to tremendous weight loss and premature death, both of which severely
impact the profitability of mink farming
Currently no therapies are available and vaccination has been a failure; it
exacerbated the disease (Bloom et al., 1994). For producers who have AD in their mink
herds, their only recourse is to pelt all animals or to take a chance that the disease will not
afflict a significant portion of their animals. Therefore, a modality needs to be developed
that could boost the susceptible animals' immune responses in an appropriate manner to
allow mink to survive AD. Such a treatment would allow the mink industry to remain a
profitable endeavor.
Extensive studies suggest that there is a genetic predisposition to AD. Some mink
breeds, like those designated as sapphires or having dark coat color, are much more
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susceptible to chronic lethal AD than other breeds such as the wild type strains (Bloom
et al., 1994). In addition, many immunological studies have suggested that a'n abnormal
immune response in susceptible animals may cause the pathology of AD (reviewed by
Aasted and Leslie, 1991; Mori et al., 1991; Kanno et al., 1992; Bloom et al., 1994).
There are two kinds of immune responses based on the cytokine profile expressed
during immune response. Thl type cells are involved in inflammatory responses, release
of interferon gamma (IFN-y), interleukin-6 (IL-6), and tumor necrosis factors (TNF-a, ~),
activation of macrophages, induction of CD8+ cytolylic T-cells and clearance of viral and
intracellular infection. Th2 cells are involved in the anti-inflammatory responses and in
stimulating antibody production by B-cells. In addition, Th2 type cells do not promote
tissue damage as do Thl cells, the damage by these latter cells being mediated by release
oflL-3, 4, 5, 6 and 10. A Thl predominance leads to the suppression of Thl cytokines
such as IL-12 and IFN-y.
From early studies of AD (Hahn and Hahn, 1983; Bloom et al., 1994), it is
apparent that the immunological response to AD is overwhelming humoral
(hypergammmaglobulinemia)

and mediated by Th2 type cytokines, especially IL-6.

Perhaps not coincidentally, human diseases (e.g., Castleman's disease) that are
characterized by hypergammaglobulinemia

are also associated with high levels of IL-6

production. Based on these findings, AD may be a virus-induced cytokine disorder; a
syndrome of chronic, inappropriate production of IL-6 and perhaps other Th2-type
cytokines (Bloom et al., 1994). Perhaps, if one could modulate the immune response in
AD-infected animals to a largely cell-mediated response with Thl-type cytokines instead
of the typical Th2 cytokine response, the severity of AD might be diminished or perhaps
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even prevented. A pertinent observation for the treatment of AD in mink is that an
attenuated vaccine only enhances AD (a Th2 response), leading to an especially extreme
B cell hyperplasia, while immunosuppressive therapy has been shown to slightly
ameliorate the severity of disease, e.g., preventing AD lesions (Cheema et al., 1972).
One of the compounds chosen, levamisole, does not directly modulate the B cell function
of producing antibody (Amery and Harig, 1984). The other compound, isoprinosine,
actually enhances B cell antibody production in the presence of pokeweed mitogen
(Tsang et al., 1984). Thisa result is not a desirable effect in AD, where over-production
of antibody leads to fatal disease.
There is considerable evidence for an immunomodulatory role for a cytokine,
transforming growth factor beta (TGF-~). It both potentiates and inhibits various
functions of the immune system in its regulatory role, depending on when and where it is
expressed. Therefore, the regulatory functions ascribed to TGF-~ sometimes appear to be
in opposition. However, its potent effects on immune cells in vitro are reflected in the
various effects it has in a variety of animal model systems, strongly suggesting an
important role in immune disorders such as autoimmune disease (Derynck and Choy,
1998).
A finding relevant to the potential immunotherapy of AD is that exogenous
administration of TGF-~ in vivo markedly depresses inflammatory and immunological
responses. For example, TGF-~ delays the onset of experimentally-induced arthritis in
mice, a disorder involving immune complexes (Brandes et al., 1991). In addition, TGF~

also regulates expression of primary antigen presenting cells, which activate T-

lymphocyte responses (Steinman, 1991) that are responsible for correct processing of
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virus antigen. Thus, it is conceivable that TGF-13could elicit a Th 1 response adequate
enough to ameliorate AD by inducing appropriate processing of AD antigen.· Finally,
TGF-131 seems to potently inhibit cell proliferation and is able to induce apoptosis
(programmed cell death) in B cells (Gordon et al., 1994) in addition to reducing the
secretion of immunoglobulin from activated B cells (Stavnezer, 1996). These
mechanisms suggest that TGF-131 may be able to down-regulate what appears to be a B
cell hyper-response such as is seen in mink with AD.
Another set of compounds that appear to have useful immunomodulatory
properties is dehydroepiandrosterone (DHEA) and its analogs. DHEA has been shown
to have immunomodulating effects in several experimental infections involving viruses
and protozoans (Rasmussen et al., 1991; Mulder et al., 1992; Uozumi et al., 1996; Loria
and Padgett, 1998). In HIV infections, 16a-bromoepiandrosterone (a-epi-Br), an analog
of DHEA, may have shifted cytokine production to a Thl response and increased
circulating activated immune effecter cells (Freilich et al., 2000). This activity appeared
not to be androgenic, since the compound only bound weakly to the androgen receptor.
Thus, DHEA and its analogs and TGF-131 may be able to promote Thl cytokine-type
responses that could afford protection for mink from chronic lethal AD.
Therefore, we attempted to develop several approaches for treating experimental
AD using TGF-131 and epiandrosterone analogs. We tested the hypothesis that treatment
of AD-infected mink with TGF-131 or epiandrosterone-like compounds would ameliorate
the development of the AD as shown by enhanced survival time of the animals.

5
Literature Review

This review considers several aspects of a Aleutian disease (AD). After an
overview of current information about the structure and function of the AD virus (ADV)
genome, the major clinical forms of AD are discussed. This is followed by summary of
recent pathogenesis studies providing potential insight into the genesis of the immune
disorder.

Aleutian Disease of Mink
AD is an immunopathological disorder of mink induced by persistent infection
with ADV (Porter et al., 1980). It is a naturally occurring virus infection caused by a
virus from the family Parvoviridae. The virus can be detected in saliva, urine, and feces
and the virus can persist for long periods in the environment. During the virus life cycle,
certain obligate intermediates of ADV replication are produced. These include
replicative forms of ADV DNA, viral messenger RNA (mRNA), various proteins,
progeny genomes, and infectious progeny virus (Bloom et al., 1994). A major goal of
ADV research is to relate virus infection to the pathogenesis of the clinical syndromes.
AD is a persistent viral infection of mink. In the early 1940's a spontaneous
mutation resulting in a dark blue coat color occurred in ranch-raised mink in Oregon and
was designated the Aleutian mink coat color (Alexandersen, 1986); this mutation is
homozygous recessive for the Aleutian gene a. In the early 1950' s, as the Aleutian mink
were continuously in- bred, a chronic wasting disease was noticed in many of them. It
was mainly characterized by weight loss but on occasion some mink would have
abnormal hemorrhaging from the mucous membranes. A syndrome involving the
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kidneys, the liver and lymphoid tissue of aa mink was reported, and was referred to as
AD (Hartsough and Gorham, 1956). It first seemed that only Aleutian mink 'were
affected; however, it has been subsequently shown that all genotypes of mink are
susceptible to the disease, but mink homozygous for a gene develop more severe disease
with a more rapid course. Mortality from AD can be as high as 100% in Aleutian mink.
The disease is not as severe in other breeds. Wild-type mink known as demi (brown), are
least affected, with about a 6% mortality. It appears that a small percentage of nonAleutian mink may either recover or live for years with AD (Porter et al., 1980).
Clinically, AD is characterized by gradual loss of weight, anemia, and uremia
ulceration of oral mucosa and in rare occasions, nervous signs. The gross lesions include
emaciation (Fig. 1. 1), hepatomegaly with small pinpoint pale foci scattered through the
parenchyma, generalized lymphadenopathy with the spleen and lymph nodes two to four
times their normal size, nephritis characterized by enlarged kidneys with widespread
petechiae early in the course and by shrunken pale kidneys with cortical cysts during the
later stages. Histologically, there is widespread proliferation and infiltration of plasma
cells in practically all organs (Obel, 1959; Henson et al., 1992). These cells are mostly of
the preivascular type early in the disease. The plasmacytosis leads to a marked
hypergamma-globulinemia, which may exceed 50% of the total serum proteins. The
glomeruli in affected kidneys are relatively a vascularized and contain a large amount of
slightly granular, eosinophilic material. Mononuclear cells proliferate in the liver. In the
early stages of the disease the all infiltrate is a mixed population of lymphocytes,
histiocytes, and immature plasma cells. Later, mature and immature plasma cells
dominate. In addition, there is a progressive renal disease characterized by mesangial
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proliferative glomerulonephritis and severe interstitial nephritis comparable to that seen
in human diseases such as systemic lupus erythematosus (Bloom et al., 1994). Additional
symptoms include decreased fertility, abortion, acute pneumonia in kits, and chronic,
persistent infections, all of which severely impact the profitability of mink farming
(Porter et al., 1980).

ADV Genome Structure, Protein, and Replication
The organization of the 4,748-nucleotide ADV DNA genome (Bloom et al., 1990)
resembles other autonomous parvoviruses in that there are major right and left open
reading frames, and palindromic structures at both 3' and 5' termini (Bloom et al., 1990).
The nucleic acid consists of a 4.8 kilo base single-stranded DNA (Mayer et al., 1983).
The size of AD virus particles ranges from 22 to 25 nm. Each 22 to 25 nm particle
contains only a single strand of DNA, the minus sense strand in> 90% of virions (Bloom
et al., 1993). The virus is non-enveloped and has cubic symmetry and contains 32
capsomeres. The density of the complete virus in cesium chloride (CsCl) is 1.39 to 1.42
g/cm 3 (Berns and Labow, 1987).
Permissive replication of the non-pathogenic strain of virus, ADV-O (ADV-Utah
1 by Gorham) in Crandell feline kidney (CRFK) cells resembles that of other
parvoviruses (Bloom et al., 1990). After adsorption and uncoating, the single-stranded
genome is converted into a variety of double-stranded replicative forms, from which the
single-stranded genomes are derived. The number of DNA molecules in an infected cell
is large, ::::105 copies of both duplex replicative forms and single-stranded virion
molecules per infected cell (Bloom et al., 1985; Alexandersen and Bloom, 1987).
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During the infectious cycle, four viral mRNAs (Rl, R2, R2', and RX) are
synthesized from a promoter at map unit 4 (P4) and one mRNA (R3) from another
promoter at map unit 36 (P36) (Alexandersen et al., 1988a). Rl, R2, and R3 terminate
with a polyadenylation signal located at map unit 92, whereas R2' and RX utilize a
termination signal at map unit 53. Cells permissively infected with ADV contain> 105
copies of viral mRNA (Alexandersen et al., 1988b), and all the RNA species are
complementary to single-stranded virion DNA.
The 2.8-kb R3 mRNA codes for the two capsid proteins, VP-1 (P85) and VP-2
(P75), which arise by alternate initiation on the same mRNA (Alexandersen et al., 1988a;
Christensen et al., 1993). VP-2 coding sequences are fully contained within the large
right open reading frame, whereas VP-1 contains additional sequences joined to the
amino end of VP-2 (Bloom et al., 1982; Alexandersen et al., 1988a; Christensen et al.,
1993).
The mRNAs specified by P4 encode at least two nonstructural (NS) proteins
(Bloom et al., 1982; Alexandersen et al., 1988a; Christensen et al., 1993), analogous to
those found for minute virus of mice (MVM) and other parvoviruses. The ADV NS
proteins are derived by complex, differential mRNA splicing of the major left open
reading frame and smaller open reading frames in the mid-genomic region (Alexandersen
et al., 1988a). All of the ADV NS proteins share a common amino terminal portion of 59
residues, but there are unique regions for each NS protein as well.
The large 4.3-kb mRNA, which contains almost the entire left open reading
frame, codes for the 71-kDA (Bloom et al., 1983) major nonstructural protein 1 (NSl), a
protein with pleiotropic function (Bloom et al., 1983; Christensen et al., 1993).
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Parvoviral NS 1 is required for viral genomic replication and excision of single-stranded
virion DNA from double-stranded replicative form DNA (Bloom et al., 1983; Rhode,
1985, 1989; Christensen et al., 1993). In addition, NSl functions as a transcriptional
regulator by trans-activating the P36 promoter and thus controlling the level of capsid
protein mRNA (Ahn et al., 1989; Doerig et al., 1990; Hanson and Rhode 1962). NSl can
also regulate its own transcription and may be involved in influencing the level of
cytopathology induced by the virus (Labow et al., 1986; Berns and Labow, 1987; Ozawa
et al., 1988; Legrand et al., 1993).
Both the 2.8-kb R2 and 0.85-kb R2' mRNAs code for a smaller nonstructural
protein 2 (NS2), -13.4 kDa in size (Cotmore and Tattersall, 1986; Alexandersen et al.,
1988a). The difference between R2 and R2' is that R2' terminates at a polyadenylation
site at map unit 53, whereas R2 continues with a long 3' noncoding region that ends at the
map unit 92 polyadenylation signal (Alexandersen et al., 1988b). The function of NS2 is
not well understood, but it is required for efficient replication in a cell-type specific
fashion (Brandenburger et al., 1990; Brownstein et al., 1992). It should be noted that the
ADV R2 transcript also contains all the required coding sequences necessary for
production of the capsid proteins, and in fact, a recombinant baculovirus expressing this
mRNA direct will synthesis of small amounts of capsid proteins in addition to NS2
(Christensen et al., 1993).
The 1.1-kb RX mRNA may specify an additional nonstructural protein,
tentatively designated as NS3 (Alexandersen et al., 1988b). A baculovirus containing
this gene directs expression of an appropriate sized protein in insect cells (Christensen et
al., 1993). NS3 has not been found for the other autonomous parvoviruses; however,
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MVM has several different isoforrns of NS2. Thus, if NS3 is a real viral gene product,
it may subserve the function of NS2 isoforms. Preliminary sequence analysis of
additional strains of ADV suggests that the requisite splicing junction for RX may be
lacking from the RNA Rl in some in vivo derived ADV strains.
At the peak of replication, viral antigen is detected in cells associated with the
distribution of macrophages in lymphoid organs and Kuffer's cells liver, and the location
of viral antigen is cytoplasmic, suggesting that the virus is sequestered in phagocytic cells
(Porter et al., 1969). At later times in the infection, virus levels decrease significantly,
but complete viral clearance is infrequently observed (Larsen and Porter, 1975). Because
ADV occurs in infectious immune complexes and is probably sequestered in phagocytic
cells, the simple identification of virus, virion proteins, and DNA is not adequate proof
that actual replication is occurring in a particular site. Therefore, it is necessary to use
reagents that mark obligate intermediates of active viral gene expression (e.g., replicative
from DNA, mRNA, and nonstructural proteins; Alexandersen et al., 1988a).
Virion DNA is widespread in lymphoid and phagocytic organs. It is apparently a
sequestered in cells of the reticuloendothelial system, including follicular dendritic cells
(FDC) and macrophages (Kanno et al., 1992). This suggests that some virus might be
bound as immune complexes to the FDC (Mori et al., 1991). Replicative from DNA and
mRNA, the two obligate intermediates of de nova virus replication, are present at greatly
reduced or restricted levels as compared to permissively infected mink kit lungs or cell
culture (Alexandersen et al., 1988a). Nevertheless, evidence suggests that a small
percentage of macrophages support viral replication and gene expression (Mori et al.,
1991) and that FDC and lymphoblasts may also be targets. Importantly, the number of
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cells sequestering virion DNA is at least 10 times greater than the number containing
ADV RNA, suggesting that the number of cells containing ADV support an active
infection (Alexandersen et al., 1988a).
At later times after infection, when the immune disorder is evident, the amount of
virus is further reduced (Alexandersen et al., 1988a). Virion DNA remains detectable in
the sequestered pattern observed at earlier times, but only in cells in lymphoid tissues that
appear to be macrophages (Mori et al., 1991). Furthermore, throughout the course of
disease, other organs such as nucleated blood cells, bone marrow, liver, kidney, and
spleen also contain viral sequences (Alexandersen et al., 1988a).

AD of Newborn Mink
Less than 2 weeks after neonatal infection, mink kits can develop an acute
interstitial pneumonia (Alexanderson, 1986). Within a few days, they succumb to a fatal
respiratory distress syndrome characterized by parenchymal hemorrhage, extensive
atelectasis, and hyaline membrane formation. With highly virulent strains, incidence and
mortality are >90%. In contrast, the incidence of disease is between 50-70% and
mortality is 30-50% with low-virulence strains. Survivors develop typical lesions of the
classical chronic adult form of AD regardless of the infecting strain (Alexanderson et al.,
1994).
In AD of newborn mink, there is no question of where the virus is replicating.
The disease in kits is characterized by ADV infection of type II alveolar cells, with capsid
and nonstructural proteins readily demonstrable in the infected cells. Approximately
10% of the type II cells are actually infected in these animals (Alexanderson et al., 1987).
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Infection of these cells, which produce pulmonary surfactant, presumably leads to a
functional surfactant deficiency and to the fatal severe respiratory distress. Although the
main target in kits is the type II alveolar cell, virus replication occurs in cells of other
tissues, such as in the lymph node, spleen, kidney (Alexanderson et al., 1987;
Alexanderson, 1990). In situ and Southern blot hybridization studies indicate that the
levels of replicative intermediates in the infected alveolar type II cells are very high, on a
5
par with those found in cell culture (::::::10
copies per infection cell; Alexanderson et al.,

1987). This apparently unique susceptibility of the type II cells in the newborn period
may be due to several factors. First, during the immediate postnatal period, type II
pneumocytes are rapidly dividing and rapidly dividing cells are, in general, more
susceptible to parvoviruses. In addition, newborn mink kits are not able to mount as
rapid an immune response as adults (Alexanderson, 1986; Alexanderson et al., 1994).

Pathogenesis of Aleutian Mink Disease
Most pathogenesis studies have involved experimentally induced infections in
which uninfected mink are exposed to spleen homogenates from other infected mink,
either intraperitoneally or intranasally. Under these conditions, not only are viral
particles introduced, but also antibodies that may enhance uptake of the virus into cells
and other inflammatory mediators are also inoculated with virus. It has been assumed
that the virus is naturally transmitted via a mucosa! route where it penetrates the
epithelium of the gastrointestinal or respiratory systems. The incubation period in natural
infections appears to be longer than that in experimentally-induced infections, indicating
possible fundamental differences in the pathogenesis of disease between natural and
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experimentally-induced infection. In experimentally infected mink, a three to ten day
interval may exist between appearance of viral DNA in blood leukocytes, as determined
by the polymerase chain reaction (PCR), and appearance of antibody. When mink are
first infected with the virus, there are large amounts (10 7- 108) of virus particles in the
blood before antibody appears. With the appearance of antibody, the virus titer in the
blood decreases. After a few weeks, the virus either disappears or can be detected in only
small quantities in the blood. In demi mink, there is a good linear relationship between
the amount of virus in blood after 6 months of infection and lesions. In dark mink, there
is not a linear relationship because smaller amounts of virus in blood can be associated
with severe lesions.
A simplified scheme for a grand unified theory of AD pathogenesis might be
portrayed as follows: An initial round of AD virus infection occurs in antigen presenting
cells, perhaps in macrophages, follicular dendritic cells (FDC), or an as yet in an
unrecognized primary target cell (such as renal tubular cells), providing an initial burst of
virus that stimulates the immune system to produce anti-ADV antibody. Further ADV
antigen stimulation leads to preferential induction of Th2 helper T-cell types, and the
creation of a Th2 cytokine-laden milieu in lymphoid follicles. The FDCs present ADV
antigens to B cells, programming them for differentiation into anti-ADV antibody plasma
cells. In a subpopulation of macrophages, a restricted, antibody-dependent infection
(ADI) leads to the production of the cytokine, IL-6. IL-6 mediates a polyclonal
stimulation of the programmed B cells and synthesis of large amounts of antiviral
antibody. The stimulated B cells also release IL-6 and stimulate other B cells to follow
the same path. In the face of the persistent infection, the antiviral antibody reacts with
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virus, creating a chronic load of virus-containing immune complexes. This sustains a
repeating cycle of virus loading onto FDC and macrophages, programming of anti-ADV
B-cells and production of IL-6. The self-reinforcing circuit that results impairs normal
regulatory mechanisms, leading to hypergammaglobulinemia and plasmacytosis.
Deposition of immune complexes in glomeruli and arteries results in immune complex
disease. Virus also infects cells in the renal tubular epithelium, and the infected cells
become a target for T cells and other lymphocytes primed to react against infected cells,
leading to interstitial nephritis.

Transforming Growth Factor-/3 (TGF-/3)

The initial identification of transforming growth factor (TGF-~), was based on its
ability to reversibly induce phenotypic transformation of elect fibroblast cell lines
(Derynck, 1992). Although transforming growth factor (TGF-~) was originally named
for its ability to reversibly cause a phenotypic transformation of rat fibroblasts (Moses et
al., 1981), numerous bioassays describing cartilage inducing factor (Seyedin et al., 1985),
glioblastoma immunosuppressive factor, myoblast differentiation inhibition factor
(Fiorini et al., 1986), and epithelial growth inhibitor (Holley et al., 1980) were found to
be measuring the same TGF-~ protein.
The initial detection of TGF-~ activity in a transformation assay suggested a role
for TGF-~ in malignant transformation and tumor development. It is now well
established that the activities of TGF-~ are by no means restricted to tumor cells, but that
TGF-~ exerts a multiplicity of biologic activities on most cells, both normal and
transformed, and regulates many cell physiologic processes. The biologic response to
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TGF-~ is complex and depends not only on the cell type but on the physiologic
conditions. Furthermore, TGF-~ also plays an important role in the control of the
immune response and wound healing and in the development of various tissue and
organs.

Genomic Organization of the TGF-/J1 Gene

Multiple species of TGF-~ which are encoded by different genes have been
identified. TGF-W s are disulfide-linked polypeptide dimers of molecular mass 25 kDa.
Each mature chain is 112 amino acids in length and is derived from a larger precursor. In
mammalian genomes, at least three genes encode TGF-~ precursors (TGF-~ 1• ~ 2 , and ~3 ).
TGF-~ 1•

~ 2,

and ~3 are each coded by a single gene located on separate chromosomes, m

humans on 19q13.1, lq41, and 14q23 (Fujii et al., 1986; Barton et al., 1988).
The human TGF-~ 1 precursor is encoded by seven exons. The similarity of their
seven exon structures and the high degree of conservation of their exon/ intron borders
indicate that these genes are derived from a common ancestor (Derynck et al., 1987).
TGF-~s have unique 5' long untranslated regions (UTR). For TGF-~ 1, there is a region of
841 untranslated base pairs and 50 untranslated base pairs in 7 exon. In contrast to TGF~2

and ~3 promoters, ~ 1 does not have a traditional "TAT A" sequence. Instead, just

upstream of the first transcriptional start site, the TGF-~ 1 promoter has a very GC-rich
region with several Spl binding sites.
The TGF-~ 1 precursor is 390 amino acid. All the potential N-linked glycosylation
sites lie outside the bioactive domain. The TGF-'3 1 precursor contains an amino-terminal
hydrophobic signal sequence (aa 1-23) for translocation to the endoplasmic reticulum to
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undergo exocytosis. The pro-region (aa 24-278) guides the correct folding and
disulfide bonding of the bioactive domain during TGF-f3 synthesis (Gray and Mason,
1990). The bioactive domain (aa 279-390) is the carboxyl-terminus of the precursor,
preceded by a sequence of four basic amino acids, which form the cleavage site.
Intracellular proteolytic cleavage probably occurs by furin peptidase after dimerization of
the precursors (Dubois et al., 1995). Active TGF-f3 is usually a homodimer but naturally
occurring TGF-f31, f32 and f33 heterodimers can also be found.
The amino acid sequences of all three mature TGF-f3 isoforms are strictly
conserved; there is 98-100% identity between chicken and human. The evolutionary
pressure to retain such a degree of conservation suggests that the functions of each
isoform are critical. The degree of homology of the bioactive domain between the three
human isoforms ranges from 70-80%, with much greater sequence divergence in the
precursor region.

Structure ofTGF-/3
Since the original construction of the cDNA clone of TGF-f3, extensive protein
characterization and cDNA analysis have revealed a large group of structurally related
secreted factors. In addition to being multifunctional, TGF-f3 is a member of a large
family of factors with widely diverse activities. The TGF-f3 superfamily was first
recognized in the late 1980s (Sporn et al., 1987). Since then, the superfamily has grown
to more than 25 members, with some of the molecules being grouped into four distinct
subfamilies owing to highly related structures (Roberts and Sporn, 1990). Each precursor
contains an N-terminal signal peptide, a long prosegment, also called the "latency-
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associated polypeptide" (LAP) and a 112-amino-acid C-terminal polypeptide that
constitutes the mature TGF-13monomer. This monomer is cleaved from the remaining
precursor segment following a tetrabasic peptide.
The active form of TGF-13is a hydrophobic, disulfide-linked dimer of the Cterminal segment of the pre-pro-TGF-13 (Derynck et al., 1985; Cheifetz et al., 1987). The
three TGF-13species, with a sequence identity of 70-80% (Derynck et al., 1988), are thus
generated as homodimers of two identical C-terminal polypeptides, although
heterodimers consisting of TGF-131 and TGF-132 have also been isolated (Cheifetz et al.,
1987). The biologic relevance of the heterodimeric species is unclear, especially as they
presumably correspond to only minor species. The 112-amino-acid mature TGF-13
polypeptide includes nine conserved cysteines, eight of which are paired. All cysteines
form intra-chain disulfide bonds, with the exception of one intermolecular cysteine bridge
responsible for dimerization. Three-dimensional structure analysis has revealed an
extended butterfly-like structure of the TGF-132 homodimer, rather than the compact
globular structure frequently seen in highly stable and temperature and protease resistant
growth factors (Daopin et al., 1992). The sequence between the fifth and sixth cysteine,
which has the most sequence divergence among the different TGF-13isoforms and the
other members of the TGF-13superfamily, is exposed at the surface of this molecule and
plays an important role in the determination of the specificity of ligand-receptor
recognition.
The prosegments of the three TGF-13precursors show a sequence identity of only
25-35%. Nevertheless, some structural elements are strongly conserved, suggesting
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critical roles either in the function or in the folding of this prosegment. Among these
conserved features are three cysteine residues and two N-glycosylation sites.' Two of the
three cysteines are involved in intermolecular disulfide bridge formation (Miyazono et al.,
1988; Derynck et al., 1998). Finally, a hydrophobic stretch of amino acids closely
following the signal peptide is conserved as well and may be involved in the folding of
the precursor segment (Lopez et al., 1992).
Biochemical characterization has shown that TGF-B is normally secreted as a
protein complex, consisting of the mature TGF-B homodimer and two prosegments,
which interact non-covalently with the mature dimer. The participation of mature TGF-

Bin this complex

prevents it from interacting with the TGF-B receptors, thus rendering

this complex inactive or latent. Based on antibody recognition researches, it is likely that
this interaction of TGF-B with the much larger prosegments leaves little of the mature
TGF-B exposed at the surface of this complex (Wakefield et al., 1988).
The expression of the three TGF-B isoforms is differentially regulated. Thus,
different inducers or exogenous agents have distinct effects on the secretion of individual
TGF-B species. This differential regulation of expression is largely due to a characteristic
and independent pattern of transcriptional regulation of the three TGF-B species, which is
in turn regulated by distinct control elements in the promoters of the genes (Roberts et al.,
1991). In addition, all three TGF-B isoforms have long 5' untranslated sequences which
most likely play an isoform specific role in the regulation of translation efficiency
(Derynck et al., 1985; Kim et al., 1992).
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Receptors and the Cytokine Network

Low numbers of high-affinity receptors for TGF-~ are found on most normal
resting and transformed mammalian cells. The two major TGF-~ receptors, types I and
II (TGF~RI, 53 kDa, and TGF~RII, 70-80 kDa), are both serine/ threonine kinases used
by many of the mitogens, whose action TGF-~ opposes (Derynck, 1994; Massague et al.,
1994). Each has a small extracellular region, a single transmembrane domain, and an
intracytoplamic serine/ theronine kinase domain. The large numbers of cysteines in the
extracellular domain with a cluster of three just upstream of the transmembrane are
characteristic of all signaling receptors of the TGF-~ superfamily. Almost all cells,
regardless of their origin, express TGF-~ receptors and bind TGF-~ with high affinity.
Signaling has been shown to require the formation of a trimeric complex consisting of
both TGF-~ receptors I and II. The type III receptor, a transmembrane proteoglycan, has
a short, highly conserved cytoplasmic domain without an apparent signaling motif
(Lopez-Casillas et al., 1993). Other binding proteins for TGF-~ include
cxrmacroglobulin, fibronectin and ~-amyloid precursor.
The cloned type I receptor has a high-affinity binding for TGF-~ 1 and TGF-~ 3 but
not TGF-~ 2 (Lin et al., 1992). The kinase domain of TGF~RII is flanked by a spacer
between the domain and the transmembrane region and a carboxy-terminal tail. The
kinase domains of the associated type II receptors of the superfamily show less than 40%
amino acid sequence identity, suggesting that this divergence might be involved in
conferring some signaling specificity.
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In addition, type I receptors have a much shorter carboxyl-terminal tail and the
extracellular domain has a distinct clustering of five cysteines. The type II receptors can
bind ligand directly from the medium, while type I receptors cannot (Massague et al.,
1994). Type I receptors recognize ligand that is bound to type II receptors, with which
they form a complex, probably a heterotetramer. If distinct heterodimers have different
functional specificities, this could provide another way of expanding the regulatory
flexibility of TGF-~ superfamily.
The role of TGF-~ in immune surveillance and immunotherapy must be
conceptualized in the context of its role as a cytokine, participating in the cytokine
network. This integrated network includes contribution and immunity. The outcome of
an immune response is the result of the balance between synergy and antagonism of
several cytokines, and dysregulation at any level can contribute to disease pathogenesis.
Like other cytokines, TGF-~ is highly potent, acting on cell surface receptors at
femtomolar concentrations (10- 15M). Since different cell types possess receptors for the
same cytokine, TGF-~ like other individual cytokines, may have multiple effects on the
growth, differentiation and function of many cell types.

TGF-/3 in the Immune System

There is considerable evidence for an immunomodulatory role of TGF-~ and its
function as a potent differentiation modulating and immunosuppressive agent (Letterio
and Roberts, 1998). In culture most cells of the immune system, such as lymphocytes,
monocytes and dendritic cells, synthesize TGF-~ that is almost exclusively TGF-~1- The
TGF-~ released by these cells is mostly not active, suggesting that activation of the latent
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complex is required before TGF-B can exert its function. The target cells are not only
the different leukocytye cell types, but also various other cell types in the immediate
tissue environment, such as endothelial cells or tumor cells, indicative of autocrine and
paracrine actions. Once activated, TGF-B exerts a variety of activities on proliferation,
differentiation and function of various cell types of the immune system.
TGF-B often inhibits cell proliferation, as has been shown for T lymphocytes, B
lymphocytes, thymocytes, natural killer (NK) cells, large granular lymphocytes, and
lymphocyte activated killer (LAK) cells (Rook et al., 1986; Kehrl et al., 1986a; Wahl et
al., 1988). Furthermore, the response may depend strongly on the state of differentiation
of the cell and on the context of cytokines to which the cells are exposed. Accordingly,
these different types of immune cells all have TGF-B receptors.
One of the cell populations, which is strongly regulated by TGF-B are the T
lymphocytes. Activated T cells secrete TGF-B and exogenous TGF-B inhibits
interleukin-2-dependent proliferation (Kehr! et al., 1986b). In addition, TGF-B also
inhibits the secretion of a variety of cytokines and in this way inhibits the effector
function of the activated cells. Thus, TGF-B inhibits the effects and/ or the production of
interferon-y (IFN-y), tumor necrosis factor (TNF) -a and-Band interleukins-I, -2, -3, and
expression of interleukin-2 receptor (Ohta et al., 1987; Letterio and Roberts, 1998). The
endogenous synthesis of the TGF-B and the increased cytokine production in TGF-B1deficient mice strongly suggests that cytokine production is under autocrine control of
TGF-P (Shull et al., 1992). The inhibition of cytokine production and the antiproliferative effect are presumably the major effector functions in TGF-B-induced
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immunosuppression, especially as it relates to the cytolytic activities of the immune
system. Accordingly, TGF-B has been shown to be a strong inhibitor of the generation
and cytolytic activity of cytotoxic T cells, NK cells and LAK cells, and to suppress the
natural and lymphokine-activated killing by large granular lymphocytes (Roberts and
Sporn, 1990).
Other evidence for the strong immunosuppressive effect of TGF-B on
lymphocytes comes from the observation that TGF-B downregulates interferon-y-induced
major histocompatibility complex (MHC) class II antigen expression by both lymphoid
and non-lymphoid cells (Czarniecki et al., 1988). In contrast to the inhibitory effects of
TGF-B on T lymphocytes, TGF-B also enhances the growth of immature lymphocytes
and inhibits T-cell apoptosis, thus allowing expansion of the effector population (Rich et
al., 1996).
Finally, TGF-B may play an important regulatory role in differentiation of T cells.
TGF-B can induce the expression of CD8 and can synergize with TNF-a to favor the
development of cells expressing CD8. Conversely, TGF-B inhibits later stages of
differentiation and thus inhibits the generation of CD4+/ CD8+ cells (Suda and Zlotnik,
1992; Takahama et al., 1994). Whereas TGF-B was initially shown to strongly promote
the generation of Th 1 cells (Schmitt et al., 1994), a subset of helper T cells with a
characteristic cytokine secretion pattern, TGF-B has recently been more clearly
implicated as a positive regulator of differentiation of Th2 cells and a suppressor of
differentiation of Thl cells (Schmitt et al., 1994).
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TGF-~ also plays an important role in the function of B cells. The expression
of TGF-~ is regulated and is likely to depend on the differentiation state of these cells.
For example, activation of B cells with Staphylococcus aureus Cowan mitogen strongly
increases TGF-~ 1 secretion without a major effect on mRNA levels, white
lipopolysaccharide (LPS) stimulates the activation of TGF-~, which is required for LPSinduced immunoglobulin G (lgG) secretion by B cells (Kehrl et al., 1986a; Snapper et al.,
1993). Furthermore, activation of the B cells by binding of an anti-IgM antibody to cell
surface IgM also induces the secretion of active TGF-~ 1 (Warner et al., 1992). The
stimulation of TGF-~ expression by B cells most likely plays an important autocrine role
in B cell function, as TGF-~ has a potent ability to inhibit cell (Gordon et al., 1994).
TGF-~ also regulates B-cell differentiation and immunoglobulin expression. Indeed,
TGF-~ suppresses the expression by activated B lymphocytes of membrane
immunoglobulin and decreases secretion of immunoglobulins of different classes (Kehrl
et al., 1986b). However, antibodies to TGF-~ decrease the secretion of various
immunoglobulin classes without affecting IgM secretion, suggesting that low levels of
TGF-~ may regulate and be required for immunoglobulin secretion (Snapper et al.,
1993). Furthermore, the presence of TGF-~ promotes isotype switching of
immunoglobulins, likely associated with differential transcriptional regulation (Coffman
et al., 1989).
TGF-~ also plays an important role in the physiology and functional regulation of
monocytes and macrophages. As with cells of many other hematopoietic cell lineages,
monocytes and macrophages secrete TGF-~ 1 in a highly regulated fashion. In addition,

24
the activation of the latent TGF-~ complex is also highly regulated. For example,
treatment of monocytes with LPS or macrophages with concanavalin A results in a
drastically increased activation of TGF-~ without changes in mRNA levels (Grotendorst
et al., 1989). In addition, TGF-~ 1 synthesis by monocytes is strongly induced by TGF~ itself (Wahl et al., 1989). Thus, TGF-~ can induce or inhibit cell proliferation

depending on the physiologic context (Fan et al., 1992). Low concentrations of TGF~ induce a chemotactic response, which may be important for the recruitment of these

cells at sites of inflammation, in activating cells to secrete a variety of cytokines which
may play a role in the inflammatory response and often associated angiogenesis, and to
increase their expression of adhesion receptors (Wahl et al., 1993). The important role of
TGF-~ is further illustrated by the inflammatory response to subcutaneous injection of
TGF-~, which elicits a sequence of events, including inflammatory cell recruitment,
fibroblast accumulation and vascular growth, which is similar to the normal inflammatory
response to injury (Roberts et al., 1986). It is thus conceivable that the release of TGF~

by activated degranulating platelets results in an influx of monocytes, which

accompanies the initiation of the inflammation, and of fibroblasts, and may explain the
appearance of fibroblasts at the site of injury (Postlethwaite et al., 1987). Following
recruitment of monocytes, the TGF-~ at the site of inflammation then presumably
activates monocytes to induce secretion of growth factors and inflammatory mediators,
that are likely to amplify further the inflammatory response and to initiate the repair
processes at the site of injury.
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In contrast to these proinflammatory activities, TGF-~ also inhibits a variety of
activities of macrophages, which result in a suppression of macrophage function and are
likely to contribute to a resolution of the inflammatory response. This drastic change in
cell response may be causally related to decreased expression of cell surface TGF~ receptors as cells mature. Thus, TGF-~ can inhibit the production of cytokines,

including interferon-y and increase the expression of the interleukin-I receptor antagonist
by macrophages (Fargeas et al., 1992; Bauvois et al., 1996). Finally, TGF-~ also strongly
inhibits the expression of nitric oxide synthetase and in this way is likely to downregulate
the antimicrobial and tumoricidal response (Bogdan and Nathan, 1993). The proinflammatory activity of TGF-~ on monocytes and the subsequent deactivating activity
on macrophages clearly illustrate the highly coordinated role of TGF-~ in the complex
response to injury and its modulatory role at the site of repair and inflammation.
Furthermore, TGF-~ also inhibits differentiation of cytotoxic CD8+ T cells, which are
instrumental in eliminating infected cells (Barra! et al., 1995).
Endogenous TGF-~ may also plays a regulatory role in limiting immune function

in vivo and in some pathologic dysfunctions of the immune system. Some new insights
into the role of TGF-~ in immune suppression and the mechanism of TGF-~ presentation
have been revealed through studies of MRUl pr mice, which develop systemic
autoimmune disease resembling human systemic lupus erythematosus, probably resulting
in part from defective apoptosis (Steinberg, 1994). These mice have high levels of
plasma TGF-~ 1 bound to IgG antibodies. The complex potently suppresses CD8+
cytotoxic T-lymphocyte responses in the presence of macrophages (Caver et al., 1996;
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Stach and Rowley, 1993). Binding to IgG could restrict or target the activity of TGF-

p to antigenic

sites where it could play an important role in suppression of autoimmune

disease (Stach and Rowley, 1993). Furthermore, the IgG-bound TGF-P complexes could
increase the susceptibility to bacterial infection and increase defects in
polymorphonuclear leukocyte function (Caver et al., 1996). Finally, TGF-P bound to IgG
results in a considerably higher (10-500-fold) activity than free TGF-P, suggesting that
this recently discovered form of delivery of TGF-P results in an efficient targeting to
specific receptors (Caver et al., 1996).
Perhaps mice in which the TGF-B.1gene is functionally inactivated by gene
targeting provide the best illustration of the endogenous role of TGF-Pi in normal
immune function and infiltration. Shortly after birth, these mice develop a multifocal
mixed inflammatory disease with rapid and massive infiltration of lymphocytes and
neutrophils in many tissues, and subsequently die (Shull et al., 1992). Thus, TGFP1deficiency results in a severe pathology with dysfunction of the immune and
inflammatory systems, which is accompanied by increased production of several cytokine
mediators of inflammation, such as interferon-y, TNF-a and macrophage inflammatory
protein-la (MIP-la) (Shull et al., 1992). These mice also show enhanced expression of
MHC class I and II antigens, circulating antibodies to nuclear antigens, and pathogenic
glomerular IgG deposits, thus resembling human autoimmune disease (Letterio and
Roberts, 1998). The enhanced expression of MHC class II antigen in TGF-P 1knockout
mice is consistent with the ability of TGF-P to suppress its expression (Czarniecki et al.,
1988).
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In summary, there is ample evidence that TGF-B is major determinant of the
immune and inflammatory response. Among the TGF-B isoforms, TGF-B 1 is probably
the major effector molecule in most contexts, and TGF-B 2 and TGF-B 3 may exert their
major normal effects outside the immune system.
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Fig. 1.1. An illustration of the postmortem lesions of AD on mink. The spleen, liver, and
lymph are enlarged, and kidney have also enlarged, pale, yellow, and mottled.
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CHAPTER2
AMELIO RA TING ALEUTIAN DISEASE IN MINK BY
TREATMENT WITH HUMAN rTGF-~ 1

Abstract

Aleutian disease of mink (AD) is an immunopathological disorder of mink
induced by persistent infection with AD virus. It is a naturally occurring viral infection
caused by a parvovirus.
AD is serious problem in mink throughout the world. A major outbreak occurred
in Summit and Morgan counties in Utah in 1994. This outbreak is still continuing and
has resulted in some mink farms deciding to stop raising mink.
The hypothesis to be tested in this research was that TGF-~ 1 treatment of mink
will inhibit or ameliorate AD in mink. The study was conducted using four groups of
mink. Each group included twenty-five mink and were treated at a different times
relative to viral infection.
At nine months, all the treated animals had low anti-ADV antibody titers, bloodurea-nitrogen (BUN), interferon-gamma (IFN-y) and circulating-immune-complex (CIC)
levels which were well within normal parameters. However, the non-treated, infected
animals all died within four months after infection. These animals had high antibody
titers and high BUN, IFN-y and CIC levels, suggesting that their kidneys were damaged
by immune complex deposition, a hallmark of AD. Comparison of survival times
between treated and non-treated animals demonstrated that treated animals survived
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almost twice as long as non-treated animals. Also, polymerase chain reaction (PCR)
assay of lymph node tissue confirmed that non-treated animals had significant levels of
virus whereas treated animals had none.
These findings support the hypothesis that TGF-~ 1 supplementation does
ameliorate the severity of AD in mink.

Introduction

Aleutian disease (AD) is an immunopathological disorder of mink induced by
persistent infection with Aleutian disease virus of mink (ADV) (Porter et al., 1980), a
naturally occurring infection caused by a virus from the Parvoviridae family. The term
"Aleutian disease" was coined because the recessive Aleutian genotype (gray coat color)
of mink has a predilection for AD. Not only is this breed of mink characterized by
extreme susceptibility to lethal, chronic AD, it also has a genetic defect called ChediakHigashi syndrome in which the lysosomes of the mink cells are very large and have some
functional abnormalities, resulting in decreased lysosomal activity and/ or fusion of
lysosomes with phagosomes in leukocytes, impairing phagocytosis (Padgett et al., 1967;
Ward et al., 2000).
The course and type of disease in ADV-infected mink is dependent on the age of
the mink. In newborn kits, an acute AD presents fatal interstitial pneumonitis
(Alexandersen, 1986). In adult mink, AD often progresses to a chronic, lethal infection
characterized by proliferative glomerulonephritis and severe interstitial nephritis due to
deposition of immune complexes consisting of antibody bound to ADV or to auto
antigens (Porter et al., 1980). The adult mink show hair loss, poor quality fur, severe
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emaciation (Fig. 2.1) and a diminished capacity to reproduce when infected with AD.
The chronic infection also leads to immune complex disease. The mortality and
morbidity of AD can reach up to 100%. These clinical signs are culminated by an early
death in both adults and kits. Once the virus is present, complete herd infection is often
imminent (Bloom, 1984).
Attempts to immunize with attenuated or killed virus have failed; they only
exacerbated the severity of the disease (Bloom et al., 1994). However, immunotherapy
using immunosuppressive drugs such as levamisole and Isoprinosine, resulted in some
slight amelioration of disease pathogenesis (Cheema et al., 1972).
When ADV is first presented in to the mink immune system, both T helper 1
(Thl) and T helper 2 (Th2) type of immune responses are activated. As the infection
becomes chronic, a shift from the Thl to a dominant Th2 response is seen. The Th2
predominance leads to the suppression of Thl type cytokines such as interleukin 12 (IL12) and interferon-y (IFN-y) (Bloom et al., 1994). This is critical due to the role these
two cytokines play in the differentiation of T-cells and Thl responses. Thus, it would be
interesting to determine if the immune response of mink exposed to ADV could be
modulated to a cell-mediated response characterized by a Thl cytokine pattern.
A cytokine of special interest for this research is transforming growth factor beta
(TGF-~), which can modulate Thl and Th2 immune responses. Two families of
"transforming growth factors" have been identified as TGF-a and ~- These are distinct
peptides with very different spectra of biological activity. TGF-a is closely related to
epidermal growth factor (EGF), whereas the family of TGF-~ proteins not only plays an
important role in cell growth control and neoplasm development but also in inflammation
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and immune regulation. TGF-~ proteins are multifunctional dimeric cytokines originally

isolated from tumor cells, with molecular weights of 25kD and exerting pleiotropic
effects on immune function.
Among the important actions of TGF-~ proteins are the recruitment and activation
of mononuclear cells, promotion of wound healing, fibrosis, angiogenesis, potent
immunosuppressive action on numerous functions of T lymphocytes (Roberts and Sporn,
1990) and modulation of cytokine production (Chantry et al., 1989). Inactivation of
TGF-~ inhibits early hematopoietic growth and differentiation, alters B cell
immunoglobulin (lg) production and class switching (Coffman et al., 1989). Inactivation
of TGF-~ inhibits mast cell, thymocyte, B cell and T lymphocyte proliferation.
In vitro studies have provided evidence that, in addition to inhibiting T
lymphocyte proliferation, TGF-~ 1 inhibits the generation of cytotoxic T lymphocyte
(CTL) activity, induction of IL-2-induced lymphokine-activated killer cell activity,
generation of natural killer (NK) cell activity from murine NK cell bone marrow
precursors (Migliorati et al., 1989), and IFN-y augmentation of NK cell activity mediated
by human peripheral blood leukocytes. It is particularly plentiful in platelets, but it is
also present in substantial quantities in mesenchymal cells, where it plays an important
role in the remodeling of connective tissue that occurs during inflammation, bone reabsorption, and wound healing.
TGF-~ 1 produced by macrophages, T and B cells and other cells generally inhibits
development and proliferation of cells in culture (Derynck and Choy, 1998). IL-2 or IL-5

(Th2-type cytokines) may modify this inhibition while at the same time enhancing the
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production of IgA.
TGF-B1 may play an important regulatory role in differentiation of T cells. TGFB1has been found to induce the expression of CDS+ on thymocytes suggesting that it has
a differentiative function in addition to its anti-proliferative activity. For example, TGFB1can induce expression of CDS+ protein and can act synergistically with TNF-a to favor
development of cells expressing CDS+. Conversely, TGF-B 1 inhibits later stages of
differentiation and thus inhibits the generation of CD4+ and CDS+ cells (Suda and
Ziotnik, 1992). Whereas TGF-B 1 was initially shown to strongly promote the generation
of Th 1 cells, a subset of helper T cells with a characteristic cytokine secretion pattern
(Swain et al., 1991), it also has more recently been more implicated as a positive
regulator of differentiation of Th2 cells and a suppressor of differentiation of Th 1 cells
(Schmitt et al., 1994). Consequently, the microenvironment in which TGF-B 1interacts
with varying concentrations of a mixture of other cytokines may determine the ultimate
behavior of this multifunctional growth factor.
Since TGF-B 1 seems to modulate both Thl and Th2 responses, we wanted to
investigate the role of this cytokine in ameliorating AD. The hypothesis to be tested in
this research was that TGF-B 1 treatment would inhibit or ameliorate AD in mink. The
hypothesis was tested by evaluating the effects of TGF-B 1 on the immune response of
AD-infected animals, on the pathological features of disease, on certain physiological
factors detectable in serum and by evaluating its effects on viral load.
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Materials and Methods

Virus
The Utah I strain of ADV was obtained from Marshall Bloom (NIH, NIAID,
Rocky Mountain Laboratories, Hamilton, MT). All animals exposed to virus were
injected with virus intraperitoneally and received 5 X 105 fluorescent focusing units of
ADV of mink. This inoculum was used to induce detectable disease within 2 to 5 months
after virus exposure.

Cells
The macrophage cell line RAW 264.7 was obtained from American Type Culture
Collection (Manassas, VA, USA). The cells were routinely passaged with in Dulbecco's
modification of minimal essential medium (GIB CO Invitrogen Corporation, Grand
Island, NY) containing 4000 mg/L glucose. The medium was supplemented with 4 mM
L-glutamine (GIBCO Invitrogen Corporation), 0.1 mM sodium pyruvate (GIBCO
Invitrogen Corporation), 0.15% sodium bicarbonate and 10% fetal bovine serum
(Hyclone Laboratories, Logan, UT).

Animals
Unmated or non-parous one-year-old female mink weighing 600-1000 g were
used. These mink were obtained from the Windy Peaks ranch facility (Franklin, ID).
This facility has been free of AD for about 6 years as determined by serological testing
and pathology results. Serum from each animal was tested by counter-immune

electrophoresis (CEP) for the presence of antibody to AD. All animals received at the
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animal research facility were negative for AD by CEP testing.
Mink were fed once daily ad libitum diet (approximately 100 g) with a fish-based
diet formulated for optimal growth, pelt quality and seasonal variations in nutritional
needs by the Mink Farmer's Cooperative of Utah (Fig. A.1).
Blood for analysis was obtained by toe clip, and when mink were sacrificed, they
were euthanized by carbon monoxide inhalation in a sealed plexiglass chamber in an
aerated room (Fig. A.2).
Animals were held to up to 9 months. Signs of disease were measured monthly
by analyzing serum samples using antibody, blood urea nitrogen, interferon gamma, and
circulating immune complex assays. Confirmation of disease was measured by
histopathological examination of kidney, liver, and spleen, and by detection of viral DNA
in the mesenteric lymph nodes. In addition, animals were weighed monthly to determine
weight loss or gain, weight loss being a symptom of AD.

Study Design

The study was designed to evaluate three different doses (200, 100 and 1 ng/kg)
of recombinant human TGF-~ 1 (rhTGF-~

1)

and one dose (500 ng/kg) of TGF-~1 inhibitor

(latency associated peptide [rhLAPTGF-~i] R&D Systems, Minneapolis, MN) at one of
three different times of administration relative to virus exposure (Table A.1). Group 1
received TGF-~ 1 two weeks prior to virus exposure, group 2 received treatment eighth
post-virus exposure and group 3 received TGF-~ 1 2 weeks after virus exposure. Twentyfive animals were assigned to each administration group, and within that group, five
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animals were designated to receive one of three doses of rhTGF-j31, rhTGF-j3 1 inhibitor,
or 0.1 % BSA in PSS (placebo). A separate group (group 4) of five animals ieceived
TGF-131 at 200 ng/kg 2 weeks prior to virus exposure, again 8 h after virus exposure and
then 2 weeks after virus exposure (Fig. A.3).
Animals were administered drug or placebo intravenously via the inguinal vein
and virus was injected intraperitoneally using a 1:500 dilution of clarified spleen
homogenate (approximately 1 X 105 fluorescent focus units). This inoculum was used to
induce detectable disease or death within 2 to 5 months after virus exposure (Fig. A.4 ).

Counter-immune Electrophoresis (CEP)
The CEP tests (Aasted and Cohn, 1982) were performed according to the
manufacturer's (United Vaccines, Inc. Madison, WI) instructions. Eight "units" of
antigen per 10 µI were added to the appropriate wells and 10 µI of serum dilutions as well
a positive control serum were added to wells in apposition to the antigen containing
wells. Electrophoresis (55 volts for 60 min) was done using Tri-Barbital buffer (pH 8.6,
Pall Gelman Sciences, Ann Arbor, Ml) as the wick buffer and 0.9% agarose (FMC
corporation) as the matrix for the precipitation reaction (Fig. A.5).
To visualize precipitin lines, the agarose-coated plate was illuminated bilaterally
from below and viewed against a dark background. When results were obscured by
hemolysis, the precipitin lines became more clearly visible by soaking the plates 15 min
in 2% saline solution. Antibody titers were expressed as the last dilution of serum at
which a precipitin line formed.

Blood Urea Nitrogen (BUN)
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Sigma Diagnostics Urea Nitrogen kit (Sigma, St. Louis, MO) was used for the
quantitative, colorimetric determination of BUN in serum at 540 nm (Crocker, 1967).
To prepare serum samples for analysis, the samples were treated with 3% cold
trichloroacetic acid (Sigma) for 5 min at refrigerator temperature. The supernatant fluid
used for the analysis was collected by centrifugation at 1500 X g for 10 min. Positive
controls from the kit were used to generate a standard curve for calculating
concentrations of nitrogen (mg/dl) detected in each sample.

Interferon Gamma (IFN-y) Assay

Interferon-y-stimulated macrophages produce large amounts of nitric oxide (NO)
by cytosolic, NADPH-dependent inducible NO synthase (iNOS) (Kim and Son, 1996).
Once cells have been stimulated by interferon-y, NO concentration can be determined by
the amount of nitrite (NO 2) accumulation in cell culture medium. Therefore, a nitric
oxide production bioassay using the macrophage cell line RAW 264.7 was done to detect
interferon-y mink sera (Kim and Son, 1996).
RAW 264.7 cells were seeded in 96-well plates flat-bottomed (Corning Costar,
NY) at a concentration of 1 x 105 cells/well. The were incubated 4-6 h and stimulated
with mink serum samples or with 25 U/ml mouse interferon-y. All samples were diluted
using a two-fold geometric dilution series. A row of wells was set aside for mink sera
from normal, untreated mink to serve as a negative control. After 24 h of stimulation at
37°C, the medium was collected from each well for measurement of nitrite accumulation.

Nitrite production was determined by adding 100 µl of Griess Reagent (1 part
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0.1 % naphthylethyleniamine dihydrochloride to 1 part 1% sulfanilamide in 2% H P0 ) to
4
3
100 µl of supernatant fluid from stimulated RAW cells in a 96 well plate and mixing
well. The absorbance was measured at 540 nm using a microplate reader. Mouse
interferon-y concentration were plotted versus absorbance values to generate a standard
curve from which NO concentration for each sample were extrapolated.
Circulating Immune Complexes (CIC) Assay

The BOHLMANN CIC-ClQ ELA Kit (ALPCO, Windham, NH) was used to
quantitative determine the amount of circulating immune complexes (CIC) detectable in
mink serum. CIC usually activate complement when formed in the host and normally are
cleared by phagocytosis. The component of the complement system that binds these
complexes is Clq. For this assay Clq was used to capture any immune complexes found
in serum samples. CIC binding to Clq was detected using an alkaline phosphatase
conjugated Protein A, which binds to the Fe region of IgG, the predominate antibody
associated with immune complexes (Wehler et al., 1981; Endo et al., 1983).
Dilutions of mink sera (beginning at 1:50) kit standards and controls were
incubated with human Clq pre-adsorbed onto microtiter wells for 1 h at room
temperature. The kit protocol for detection of CIC was then followed. Absorbance at
405 nm was read. CIC concentrations detected in various mink sera were calculated from
standard curves generated using the positive controls provided in the kit.

TGF-

/31ELISA Development Assay

52

Detection of TGF-~ 1 in serum samples was done using a DuoSet ELISA
Development kit (R&D Systems, Minneapolis, MN) and following the instructions of the
kit.
Briefly, capture antibody was absorbed onto wells of a 96-well microplate and
incubated overnight at room temperature. After washing, blocking buffer was added to
each well and the plate incubated at room temperature for 1 h. Following three buffer
rinses, diluted serum samples, standards in reagent diluent, and serum diluent, were
added to appropriate wells in duplicate, and incubated 2 h at room temperature.
Following the incubation and rinsing, detection antibody was added to each well and
incubated two hours at room temperature. Following three rinses, streptavidinhorseradish peroxidase conjugate (HRP) was added to each well, the plate sealed and
incubated for 20 min at room temperature. After appropriate rinsing, substrate solution
( 1: 1 mixture of H 2O2 and tetramethylbenzidine) was put into each well and incubated for
20 min at room temperature. After stopping the reactions with stop solution (2N H2SO4),
absorbance was read using a microplate reader set to 450 nm and 540 nm.
Mean absorbance for the standards plotted versus concentration of the standards
to generate a standard curve and mean concentrations of TGF-~ 1 in each sample were
derived from the standard curves.
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Detection of Viral DNA
Viral DNA was detected by polymerase chain reaction (PCR) amplification of

viral DNA extracted from mesenteric lymph nodes of mink with subsquent visualization
of the DNA gel electrophoresis.
Approximately 0.25 g of mesenteric lymph node tissue was digested with
proteinase K (Sigma). The DNA was then suspended in 500 µl of digestion buffer (0.01

M Tris HCl, 0.001 M EDTA, pH 7.2 TE buffer), phenol-chloroform extracted, and
ethanol precipitated using standard procedures. The sample DNA was stored at -80°C
until amplified by PCR.
Ten microliters of hydrated DNA (0.5-1.0 µg) was used for each PCR reaction.
The reaction mix consisted of the following: 0.25 µM concentration of each primer, 0.2
mM deoxynucleotide triphosphates, 50 mM KCl, IOmM Tri HCl (pH 8.8), 15 mM
MgC]z, 0.2% Triton X-100, 2.5 units of Taq DNA polymerase (total volume of 100 µl).
Primers were selected from the 5' end of the viral genome in a highly conserved nontranslated region (Bloom et al., 1988). Primer sequences were as follows, with
nucleotide positions given in parentheses: upstream primer-GATGAGCAGAGGAGAC
TGCA (224-243): downstream primer-AGTAACCTAAGCAACAGTGA

(583- 602).

The expected fragment size was 379 base pairs, representing nucleotides 224-602. For
each set of reactions, positive and negative controls were used (Jackson et al., 1996).
DNA for the positive controls consisted of 10 ng of the gel-purified amplified fragment.
Negative controls consisted of approximately 1 µg of DNA isolated from blood cells of
uninfected mink. Each cycle consisted of 1 min each at 95°C, 55°C, and 72°C. A total
of thirty cycles was done, using a thermal cycler (Singblock TED, Ericomp, Inc., San
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Diego, CA). After amplification, samples were separated on a 1.0% agarose gel in T AE
buffer. Bands were visualized with ultraviolet light and photographed using Polaroid
film.

Histopathology Examinations
Upon the death of each mink, either from AD or when sacrified the kidneys and
liverwere removed and tissues from each were sectioned, fixed and then stained with
hematoxylin and eosin. Typical pathological findings for AD included thickened
mesangium in the glomeruli with homogenous eosinophilic material (membranous
glomerulopathy), detection of multifocal infiltrates of plasma cells and lymphocytes in
the interstitium of the kidney cortex (interstitial nephritis) and also in the medulla,
multiple convoluted tubules containing eosinophilic material or granular casts, occasional
mineralization basement membranes, and portal areas of the liver with varying numbers
of infiltrated plasma cells and lymphocytes (hepatitis) randomly dispersed among the
hepatocellular cords. Samples were coded and sent to a board certified pathologist (Utah
State Veterinary Diagnostic Laboratory, Logan, UT), who examined the samples for the
above-defined pathology; abnormalities were scored as mild (+ ), moderate (++ ), and
severe (+++ ). Samples with the pathology described above were considered positive for
AD.

Statistical Analysis
Statistical significances were determined by analysis of variance and Student's ttest where appropriate. Standard deviations (SD) were determined for all mean values.
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Results

Survival Time
Infected, placebo treated animals all died of AD before the termination of the
experiment (by 5 months into the experiment), with mean survival time of 149 ± 8 days.
Mink treated with 1 ng/kg of TGF-~ 1 had survival times comparable to the infected,
placebo control group as did mink treated with TGF-~ 1 inhibitor, regardless of the
treatment regimen. Animals treated with TGF-~ 1 at 100 and 200 ng/kg had significantly
(p ::;0.05) prolonged mean survival times, again regardless of the treatment regimen. The
average survival time for the four treatments groups at these dosages ranged from 200 ±
33 days to 248 ± 17 days (Fig. 2.2). Survival increased of 10% to 60% (p ~ 0.05) were
seen in the TGF-~ 1-treated groups.

Body Weight
Mink were weighed prior to any treatment and that weight was designated "preexposure weight." The post-virus exposure weights represent the average weight of
animals in each treatment group just prior to death or sacrifice. Mink which were
untreated and not exposed to virus had significant weight increases relative to the
infected, untreated (placebo) groups (Fig. 2.3, p < 0.01) and suffered from severe
emaciation (Fig. 2.1 ).
All TGF-~ 1-treated animals lost some weight compared to pre-exposure body
weights (Fig. 2.3). However, those mink treated with TGF-~ 1 inhibitor placebo group
suffered tremendous weight losses, consistent with typical AD pathology (Fig. 2.1 ).

Specific ADV Antibody Levels
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AD may be manifested at certain stages by exhibiting elevated serum'
gammaglobulin levels. High titers of antibody (>512) are often associated with
progressive chronic AD (Bloom et al., 1994). Therefore, serum was analyzed for ADVspecific antibody as a marker for progression to chronic disease.
Animals treated with TGF-f31 at 100 and 200 ng/kg had significantly lower antiADV antibody titers than did the placebo-treated mink or animals treated with TGF-f31
inhibitor (p ~ 0.05). The lowest average antibody titer occurred in the TGF-f31 group 2 in
which treatment was given 8 h post virus inoculation (Fig. 2.4). The antibody titers for
the placebo groups and the TGF-f31 inhibitor-treated groups exceeded the threshold
(>512) commonly accepted as the point at which mink are likely progress to chronic AD
often culminating in death (Bloom et al., 1994).
Comparing the mean average CEP titers between the groups of TGF-f31-treated
mink showed that those treated with TGF-f31 at 100ng/kg in group 2 and those animals
treated with TGF-f31 at 200 ng/kg in group 4 had significantly decreased mean CEP titers
218 (p < 0.001) and 256 (p < 0.01), respectively, compared to controls group.

Serum Levels of Urea Nitrogen
Detectable levels of urea or other nitrogenous compounds in serum are sometimes
indicative of damage to the kidneys, probably at the level of readsorption through the
tubules. The BUN test used in this study provides results which often correlate with
chronic renal failure due to distal tubule transport malfunction.
Blood levels of nitrogenous compounds for all groups of mink were higher after

virus exposure when compared to the pre-virus exposure, pretreatment levels (Fig. 2.5).
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However, animals receiving treatment with TGF-~ 1 at 100 or 200 ng/kg had,' in general,
significantly lower BUN levels after virus exposure compared to those levels in mink not
treated with TGF-~ 1 or treated with TGF-~ 1-inhibitor (p < 0.05, Fig. 2.5).

Serum Gamma Interferon (IFN-y) Activity

Levels of interferon-y, a Thl type of cytokine, were assessed as a reflection of the
effects of TGF-~ 1 treatment on Th 1 type responses using the method whereby mouse
macrophage cells are stimulated in vitro with a serum sample putatively containing
interferon-y and looking for a proportionate production of nitric oxide (Kim and Son,
1996).
Serum interferon-y levels were higher in all groups after virus exposure and/or
treatment than in sera taken from mink prior to those events (Fig. 2.6). Levels of
interferon-y were 1.2- to 3-fold lower in animals treated with TGF-~ 1 at 100 or 200 ng/kg
than the levels in the placebo groups or in the TGF-~ 1 inhibitor mink. The levels in the
mink treated with TGF-~ 1 at 1 ng/kg seemed to be midway between the levels detected in
the other treatment groups described above.

Circulating Immune Complex (CIC)Ttiters

Circulating immune complexes (CIC) are formed by the interaction of antibodies
with immunogenic antigens. Immune complexes with only a slight excess of antibody or
antigen are soluble and activate complement and high levels of CIC are sometimes
symptomatic of various autoimmune and other CIC-related diseases.

Since one of the hallmarks of AD pathology is the destruction of kidney tissue
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due to deposition of CIC in the kidney and subsequent antibody-mediated destruction of
the basement membrane of kidney tubules, assays were done to determine CIC levels in
mink using a commercially available kit.
CIC levels were significantly lower in mink treated with TGF-~ 1 at 100 and 200
ng/kg than those animals receiving TGF-~ 1 inhibitor or placebo-treated mink (Table 2.1,
p ~ 0.05). Animals treated with TGF-~ 1 at 1 ng/kg seemed to have CIC levels midway
between the groups discussed above. However, the CIC levels for the placebo-treated
mink and mink treated with TGF-~ 1 at 1 ng/kg, and the TGF-~ 1 inhibitor were
dramatically increased in comparison to levels detected in those same mink prior to virus
exposure and/or treatment, suggesting chronic exposure to some agent(s) like ADV.

Serum Levels of TGF-/31

The effect of treatment with exogenous TGF-~ 1 on serum levels ofTGF-~

1 in

treated mink, is shown in Fig. 2.7. In general, TGF-~ 1 levels seemed to slightly increase
in animals treated with TGF-~ 1 at 100 or 200 ng/kg compared to baseline levels. For
mink treated with TGF-~ 1, the levels seemed to remain the same throughout the duration
of the experiment. In the placebo groups and the groups of mink treated with TGF-~ 1
inhibitor the levels of TGF-r31 appeared to drop compared to the levels found inthose
groups prior to treatment and/ or exposure to virus (Fig. 2.7).

Virus DNA Levels
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To determine if virus was present in treated, infected animals, mesenteric lymph
nodes of mink (Bloom et al., 1994) were harvested and assayed for viral DNA by PCR
amplification and gel analysis from samples taken as soon after death as possible or
immediately after sacrifice.
Viral DNA was not detected in animals treated with TGF-~ 1 at 100 or 200 ng/kg
with the exception of one animal treated with 200 ng/k:g in group 3 (Table 2.2). For the
other groups of mink, viral DNA was present in the majority of animals. In mink treated
with 1 ng/k:g TGF-~ 1, viral DNA could be detected in 60% of the animals. For the other
groups, viral DNA was detected in four or five mink in each treatment regimen (Fig.
B.1).

Histopathological Examinations

Typical pathological findings for AD included thickened mesangium in the
glomeruli with homogenous eosinophilic material (membranous glomerulopathy),
detection of multifocal infiltrates of plasma cells and lymphocytes in the interstitium of
kidney cortex (interstitial nephritis) and also in the medulla, multiple convoluted tubules
containing eosinophilic material or granular casts, occasional mineralization basement
membranes, portal areas of the liver with varying numbers of infiltrated plasma cells and
lymphocytes (hepatitis) randomly dispersed among the hepatocellular cords.
With few exceptions, mink treated with TGF-~ 1 at 100 or 200 ng/kg tended not to
have visible lesions in the kidneys and liver attributable to AD (Table 2.3). Most mink
treated at the lowest dose of TGF-~ 1 did exhibit mild to severe lesions characteristic of

AD, with one animal from each treatment regimen not showing any lesions typical of
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AD.
All animals in the placebo groups or in the TGF-~ 1-treated groups were positive
for AD lesions in the kidneys and the liver; most mink being scored as having moderate
to severe pathology.

Discussion

Aleutian disease virus (ADV) causes a number of interesting disease syndromes
in mink. These syndromes include decreased fertility, abortion, acute pneumonia in kits,
and chronic and persistent infections, all severely impacting the profitability of mink
farming in Utah and throughout the world. Interestingly, the main feature of AD in
susceptible adult mink is chronic, but fatal immune complex-mediated
glomerulonephritis comparable to that seen in human disease such as systemic lupus
erythematosus (Bloom, 1984). Because of its comparative aspects to human diseases and
the substantial economic loss to the fur industries in the world, classical Aleutian disease
and the nature of the virus has been studied extensively for 3 decades (Alexandersen,
1990).
Recently, several studies have been done to understand how the virus disturbs
host immune function (Aasted and Leslie, 1991). From these studies, it has become
apparent that the initial target for ADV replication is probably the macrophage found in
the medullary sinuses of the lymph nodes of infected mink (Kanno et al., 1992).
Secondary targets are B lymphocytes, circulating macrophages and follicular dendritic
cells. The phenotype of Aleutian disease is characterized by extreme

hypergammaglobulinemia caused by the production of non-neutralizing anti-ADV
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antibodies (Alexandersen, 1990) and polyclonal antibody production, including antiDNA antibodies (Hahn and Hahn, 1983). Subsequently, plasmacytosis (Porter et al.,
1980), arthritis (Porter et al., 1973) as well as immune complex-mediated
glomerulonephritis develops. These features suggest that some step in B cell
development and/ or maturation is over-stimulated by ADV infection (Kanno et al.,
1992).
Several theories have been advanced to account for the hypergammaglobulinemia
described above (Bloom et al., 1994). Among them are i) cytokines are produced in
response to ADV infection of target cell macrophages that enhance B cell proliferation
and maturation; ii) viral components (e.g., structural proteins) might directly stimulate B
cell development and clonal expansion; iii) abnormal antigen presentation by infected
macrophages might disturb subsequent B cell development and proliferation.
In support of the first hypothesis are the findings of lsaka et al. (1993). The

cytokine of special interest for this research is TGF-~, which consists of a group of
multifunctional dimeric cytokines. Originally isolated from tumor cells, with molecular
weights of 25 kD, TGF-~s exhibit pleiotropic effects. Among the important actions of
TGF-~ proteins are the recruitment and activation of mononuclear cells, promotion of
wound healing, fibrosis and angiogenesis, and a potent immunosuppressive action on
numerous functions of T lymphocytes. There is now considerable evidence to support an
important role for TGF-~ in both the regulation of extracellular matrix accumulation and
the pathogenesis of glomerulosclerosis. Recently, Isaka et al. (1993) used an in vivo
renal transfection technique (injection of liposome-bound TGF-~ cDNA into the rat renal
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artery), which resulted in over-expression of TGF-~ 1 in glomeruli and induced marked
extracellular matrix accumulation. These and other findings support a direct role for this
cytokine in the pathogenesis of glomerulosclerosis. Since TGF-~ 1 is a disparate
modulator of cell recruitment, proliferation and extracellular matrix phenotype for
mesenchymal and non-mesenchymal cells, we wanted to investigate the role of this
cytokine in the potential amelioration of the immunopathology in the kidneys and liver of
animals with AD.
From the data of the cunent experiments, it is apparent that treated animals (TGF~1 at 100 and 200 ng/kg) had low antibody titers and BUN, IFN-y and CIC levels, most
lower than those levels detected in placebo-treated mink (see summary Table 2.4). The
infected placebo- and TGF-~ 1inhibitor-treated animals all died by four months. These
animals had high antibody titers and high BUN, IFN-y and CIC values and pathology
attributable to AD, suggesting that the kidneys were damaged by immune complex
deposition, a hallmark of AD. In a comparison of survival times between infected TGF~1-treated and placebo- and TGF-~ 1 inhibitor-treated animals, TGF-~ 1-treated animals
receiving 100 or 200 ng/kg TGF-~ 1 survived almost twice as long as untreated animals or
inhibitor-treated mink. Also, PCR assay of lymph node tissue confirmed that infected
placebo- and TGF-~ 1 inhibitor-treated animals had significant levels of virus whereas
animals treated with at 100 or 200 ng/kg TGF-~ 1 had none. These findings support the
hypothesis that TGF-~ 1treatment does ameliorate the severity of AD in mink.
The effect of TGF-~ 1 treatment on just the animals surviving the 9-month
experiment duration was assessed using the previously parameters described. Mink

63
treated with TGF-~ 1 at 200 ng/kg in all groups (group 1, 2, 3, and 4) lost significantly less
weight than the control group mink (p < 0.01), although all surviving animals did lose
some weight throughout the experiment (Table 2.4). Serum levels of BUN, IFN-y and
CIC were significantly decreased from what was detected in placebo-treated mink (p <
0.01, Table 2.4). Eleven animals (11/16) in the 200 ng/kg group and 9/13 in the 100
ng/kg treated-group had no pathology attributable to AD. No virus was detected in almost
all of the surviving animals. The antibody titer specific for ADV was also significantly
lower than the titer in mink from the control group (p:::;0.01) and typical for animals
exposed to disease that are long-term survivors. These results lend credence to the
conclusion that the various treatment regimens with TGF-~ 1 at 100 or 200 ng/kg provide
a protective effect against chronic, lethal AD, even when administered after virus
exposure. However, dosing at 1 ng/kg was not very effective.
The data in this study support the idea that a dosing regimen of TGF-~ 1 at 100
ng/kg significantly increases the survival time of mink after exposure to ADV.
Nevertheless, a small number of mink still succumbed to the chronic effects of ADV
exposure. All parameters measured indicated that using the TGF-~ 1 dose of 100 ng/kg
injected 8 h after virus injection (group 2 dosing regimen) was not effective in delaying
time to death, but that the severity of the disease was lessened within the time period
studied in that particular treatment group (Table 2.4). All parameters measured in a
subset of the TGF-~ 1 at 100 ng/kg treatment group treated with which survived were
comparable to those measured in the infected control group. However, in the survivor
group, mild to moderate lesions were still found despite treatment, and weight gains were
less, lending credence to the supposition that treatment may only delay the time to death
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and appearance of severe lesions, but not permanently alter the course of a chronic AD
infection. Similar results were seen with the TGF-131at 200 ng/kg treatment regimen.
Time to death was extended substantially and the measured parameters in surviving mink
were similar to the TGF-131at 100 ng/kg group, but again pathology attributable to AD
was still detected in the kidneys and liver of a small group of treated animals (Table 2.4 ).
Interestingly, a parameter that seemed predictive of a negative outcome was the presence
of high levels of interferon-y, a Th 1 cytokine. Interferon-y has also been shown to
correlate with pathogenesis in another immune complex-mediated

disease, systemic lupus

erythematosus (Kuroiwa and Lee, 1998). In knock-out mice, interferon-y apparently was
an important cytokine in amplifying the local immune responses of lupus induced
nephritis. Infiltrating mononuclear cells exerted their effects on resident renal cells
through secretion of soluble factors and apparent promotion of cell-to-cell contact. This
scenario may not be the case with AD because in AD large numbers of lymphocytes are
found at the lesion and not macrophages/monocytes.

Instead, the high interferon-y levels

could activate localized cytotoxic T cells by stimulating expression of MHC class I
antigen cells on putative target cells (De Maeyer and De Maeyer-Guignard,

1998), for

example, cells of the basement membrane coated with immune complexes. The latter
scenario may correlate with our findings that infiltrating lymphocytes are often at the site
of lesions associated with AD.
Whereas high levels of interferon appeared to be a predictor of a negative
outcome, high levels of TGF-131 bode well as a harbinger of survival for AD-infected
mink (Table 2.4). The 100 and 200 ng/kg doses that seemed to ameliorate the disease in
infected mink were also characterized by high serum levels of TGF-131, seemingly
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supporting our hypothesis. This is further strengthened by the fact that mink treated with
an inhibitor of TGF-~ 1 had much lower levels of TGF-~ 1 in their sera and h~d disease
equal in severity, if not greater severity, than the untreated, control animals.
From the data shown in this study, it is readily apparent that 100 ng/kg or a 200
ng/kg dosages of TGF-~ 1 were most effective in treating ADV-infected mink; the TGF-~ 1
at 1 ng/kg regimen failed to protect most mink from lethal chronic AD. The experimental
design did not allow the determination of whether the compounds ameliorated the
severity of the pathogenesis permanently, whether the lesion damage was reversible or
irreversible or if the compounds "cured" mink of the disease. However, the lack of
detection of viral DNA and the reasonably low levels of specific ADV antibody and
circulating immune complexes all suggest that the virus was cleared, thus eliminating a
continual stimulator of what appears to be type III hyper- sensitivity response. This
would support the notion that at the very least, TGF-~ 1 at 200 and 100 ng/kg dosages can
temporarily halt or significantly slow down the progression of the disease.
A venues of future research may include more practical ways to administer TGF~1

to the mink, such as by vaccination in a similar way to how the vaccination for

distemper is given. Perhaps it would be possible to combine TGF-~ 1 with one of the
vaccines that is regularly given to mink and administer both at the same time in one
injection thus being less labor-intensive for the farmer, or perhaps evaluated orally as part
of the diet to see if it could be effectively administered as a supplement in the feed.
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Table 2.1
Effect of intravenous TGF-S 1 treatment on circulating immune complexes (CIC) in mink with Aleutian disease.
Mean Circulating-Immune-Com2lex

Treatment

Group 1 (treated 2 weeks
2re-virus inoculation)
Pre-virus
Post-virus
Exposure
Exposure b

Group 2 (treated 8 h
QOSt-virus inoculation)
Pre-virus
Post-virus
Exposureb
Exposure

(~g E/ml ± SD)

Group 3 ( treated 2 weeks
QOSt-virus inoculation
Pre-virus
Post-virus
Exposure
Exposure b

Group 4
(3 treatmentst
Pre-virus
Post-virus
Exposure
Exposure b

TGF-131200 ng/kg

2.95 ± 0.90

8.25 ± 0.95*

3.12 ± 1.19

7.98 ± 1.59*

2.92 ± 1.37

9.09 ± 3.00*f

TGF-131100 ng/kg

2.81 ± 0.60

4.41 ± 0.74*

2.95 ± 0.56

3.51 ± 0.35*

2.81 ± 0.89

5.22 ± 1.85*

NDC

TGF-1311 ng/kg

2.76 ± 0.73

15.49 ± 1,97+

2.98 ± 1.16 16.36 ± 2.27*f

2.69 ± 0.98

17.15 ± 2.88*f

NDC

TGF-131-Inhibitor 2.68 ± 1.24 36.46 ± 9.02+

2.85 ± 1.22 34.52 ± 7.52+

3.06 ± 1.72 30.79 ± 3_99+

NDC

2.98 ± 0.77 28.44 ± 6.15+

3.11 ± 1.58 32.85 ± 5.95+

2.76 ± 1.12 35.84 ± 4.36+

Placebo

3.16 ± 0.99

2.95±1.16

4.16 ± 0.79*

32.38 ± 5.49+

~GF-S 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation.
bRepresents data from the last serum sample taken prior to death or sacrifice of the animal.
cND = Not Done
*p :$ 0.05 compared to placebo-treated controls.
+p :$ 0.05 compared to pre- vs. post-virus exposure.
--...)

0
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Table 2.2
Detection of ADV DNA in mink treated intravenously with TGF-P1.
Presence of viral DNA
Group No.

Treatment

ADV+

ADV-

Percentage of
mink positive
for viral DNA a

Group 1
(treated 2 weeks
pre-virus

TGF-P1 200 ng/kg
TGF-P1 100 ng/kg
TGF-P1 1 ng/kg

0
0
3

5*
5*
2

0
0
60

inoculation)

TGF-P 1-Inhibitor

4

1

80

Placebo

4

1

80

Group 2

TGF-P 1 200 ng/kg

0

5**

0

(treated 8 h

TGF-P1 100 ng/kg

0

5**

0

post-virus
inoculation)

TGF-P1 1 ng/kg
TGF-~ 1-lnhibitor
Placebo

3
5
5

2
0
0

60
100
100

Group 3

TGF-~ 1 200 ng/kg

1

4*

20

(treated 2 weeks

TGF-~1 100 ng/kg

0

5**

0

post-virus
inoculation)

TGF-~1 1 ng/kg
TGF-~ 1-Inhibitor
Placebo

3
4
5

2
0

60
80
100

TGF-~1 200 ng/kg

0

5

0

Group 4b
(3 treatments)

1

aLymph nodes of animals were harvested and evaluated for the presence of viral
DNA upon death or at the determination of the experiment.
bTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks postvirus inoculation
*p ~ 0.05 compared to placebo-treated controls.
**p ~ 0.01 compared to placebo-treated controls.

Table 2.3
Summary of histopathological findings of AD-infected mink treated with TG~-f3 •
1
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Histopathological Examination
Percentage of
animals AD+ by
Pathology

Pathology Severity
Scores
Group No.

Treatment

0

+

++

+++

%

Group 1
(treated 2 weeks
pre-virus

TGF-f31200 ng/kgb
TGF-f31 100 ng/kg
TGF-f31 1 ng/kg

3
3
1

1
1
1

0
1
2

0
0
1

25
40
60

inoculation)

TGF-f31-Inhibitor c
Placebob

0

1

2

0

100

0

2

2

0

100

Group 2

TGF-f31200 ng/kg

3

1

1

0

40

(treated 8 h

TGF-f31 100 ng/kg b

3

1

0

0

25

post-virus
inoculation)

TGF-f31 1 ng/kg b
TGF-f31-Inhibitor
Placebo

1
0
0

1
0
1

2
3
3

0
2
1

75
100
100

Group 3

TGF-f31200 ng/kgc

2

0

1

0

33

(treated 2 weeks

3

0

1

0

25

post-virus
inoculation)

TGF-f31 100 ng/kg b
TGF-f31 1 ng/kg b
TGF-f31-lnhibitor
Placebo

1
0
0

1
0
1

2
3
4

0
2
0

75
100
100

Group 4a
(3 treatments)

TGF-f31 200 ng/kg b

3

0

1

0

25

aTGF-f31 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks postvirus inoculation.
bOne animal from this group (n=5) died from bacterial infection or other causes not
attributable to AD pathology.
cTwo animals from this group (n=5) died from bacterial infection or other causes not
attributable to AD pathology.

Table 2.4
Summar~ of results from 8 months treatment of Aleutian mink disease with TGF-~ 1.a
Mean survival time
Group

Treatment

(day± SD)

Group I

200 ng/kg

207 ± 21 *

(treated

100 ng/kg

2 weeks

% AD(+)

Reciprocal

Viral DNA

Patholoy

3/5*

0

221 ±26*

3/5*

Ing/kg

170 ± 31

pre-virus

Inhibitor<

inoculation)

Average(± SD)

CEPTiter

Weight (g)

BUN (nm)

IFN-y (µM)

CIC (nm)

TGF-~(ng/ml)

25

358 ± 64**

828 ± 87*

17.9 ± 4.9*

18.l ± 3.3*

8.3 ± 1.0*

0.95 ± 0.07*

0

40

307 ± 57**

820 ± 114*

14.l ± 3.5*

12.0 ± l.7*

4.4 ± 0.7*

0.91 ± 0.06*

1/5

60

60

614 ± 150*

730 ± 120*

31.3 ± 7.0*

25.0 ±4.2

15.5 ± 2.0

0.77 ±0.02

116±9**

0/5

80

100

1126 ± 280

340 ± 22

84.J ± 17.4

40.9 ± 7.0

36.5 ± 9.0

0.55 ± 0.07*

Placebod

149± 8

015

80

JOO

1024 ±0

339 ± 24

63.8 ± 12.7

31.6 ± 2.8

28.4 ± 6.2

0.73 ± 0.05

Group 3

200 ng/kg

204 ± 9*

3/5*

0

40

410 ± 64**

808 ± 65*

23.l ±5.2*

15.5 ± 5.6*

8.0 ± 1.6*

0.88 ± 0.11 *

(treated

100 ng/kg

247 ± 17*

3/5*

0

25

218±43**

883 ± 94*

15.3 ± 3.4*

17.6 ± 4.9*

3.5 ± 0.4*

0.88 ± 0.07*

8h

I ng/kg

170 ± 38

1/5

60

75

563 ±140**

765 ± 145

33.2 ± 11.8

25.0 ± 5.3*

16.4 ± 2.3*

0.77 ±0.03

post-virus

Inhibitor

123 ± 12

0/5

100

100

1024 ±0

373 ± 22*

73.2 ± 18.3

39.8 ± 6.2

34.5 ± 7.5

0.67 ±0.03

inoculation)

Placebo

120 ± 25

0/5

100

100

922 ± 115

470 ± 60

56.6 ±9.2

37.3 + 4.2

32.9 + 6.0

0.73 + 0.04

Group 3

200 ng/kg

200 ± 33*

2/5

20

33

307 ± 57**

788 ± 103*

22.8 ±4.5*

16.6 ± 2.4*

9.1 ± 3.0*

0.84 ± 0.11 *

(treated

100 ng/kg

223 ± 28**

3/5*

0

25

327 ± 88**

853 ± 100*

15.1 ± 7.0*

16.9 ± 3.6*

5.2 ± 1.9*

0.84 ± 0.06*

2 weeks

l ng/kg

179 ± 31

1/5

60

75

666 ± 128*

655 ± 53*

29.2 ± 8.2*

23.9 ± 8.8

17.2 ± 2.9*

0.77 ± 0.03

post-virus

Inhibitor

135 ± 26

0/5

80

100

922 ± 115

380 ± 37

61.8 ± 15.7

50.4 ± I 1.0

30.8 ± 4.0

0.62 ± 0.11 *

inoculation)

Placebo

129 ± 24

015

100

100

1126±280

365 ± 39

67.6 ± 5.0

42.0 ± 11.3

35.8 ± 4.4

0.74 ±0.02

Groue 4b

200 ng/kg

248 ± 31 **

3/5*

0

25

256 ± 29

969 ± 103

10.4 ± 2.7*

16.0 ± 4.8*

4.2 ± 0.8*

1.07 ± 0.26*

Alive/total

3

Values are averages of last measurable parameters prior to death or sacrifice.
b3 times treatment: TGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation.
cLatency associated peptide, recombinant human (LAPrhTGF-~ 1 at 500 ng/kg). ct Control; PSS 0.1 % BSA
*P::; 0.05 and **P::; 0.01 compared to placebo-treated controls.
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Fig. 2.1. An illustration of the visible effects of AD on mink.
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Fig. 2.2. Effect of intravenous TGF-~ 1 treatment on survival time of mink with Aleutian
disease. Animals dying prior to day 266 days. TGF-B, was administered 2 weeks pre-, 8
h post-, and 2 weeks post-virus inoculation. After 5 months, all animals in TGF-~,
inhibitor group and the placebo group had died from AD.
*p < 0.05 and **p < 0.01 compared to placebo group.
+p < 0.05 and ++p < 0.01 compared to inhibitor group.
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Fig. 2.3. Effect of intravenous TGF-~ 1 treatment on body weights of mink with Aleutian
disease. Group 1: treated with TGF-~ 1injected 2 weeks pre-virus inoculation (A), Group
2: TGF-~ 1 injected 8 h post-virus inoculation (B), and Group 3: TGF-~, injected 2 weeks
post-virus inoculation and Group 4: TGF-~ 1 injected 3 times (2 weeks pre-, 8 h post-, and
2 weeks post-virus inoculation) (D). Animals treated with recombinant human TGF-~1
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peptide TGF-~ 1 (rhLAPTGF-~ 1) at 500 ng/kg. Placebo: 0.1 % BSA in PSS. After 5
months, all animals in TGF-~ 1 inhibitor group and the placebo group had died from AD:
*p < 0.05 compared to placebo group.
**p < 0.01 compared to placebo group.
+p < 0.05 compared to inhibitor group.
++p < 0.01 compared to inhibitor group.
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Fig. 2.4. Effect of TGF-~ 1 treatment on the anti-ADV antibody titers in mink. Group 1:
treated with TGF-~ 1 injected 2 weeks pre-virus inoculation (A), Group 2: TGF-~ 1 injected
8 h post-virus inoculation (B), and Group 3: TGF-~ 1 injected 2 weeks post-virus
inoculation and Group 4: TGF-~ 1 injected 3 times (2 weeks pre-, 8 h post-, and 2 weeks
post-virus inoculation) (C). Animals treated with recombinant human TGF-~, (rhTGF~1) at 200, 100, and 1 ng/kg. Inhibitor: recombinant human latency associated peptide
TGF-~ 1 (rhLAPTGF-~ 1) at 500 ng/kg. Placebo: 0.1 % BSA in PSS. After 5 months, all
animals in TGF-~ 1 inhibitor group and the placebo group had died from AD.
*p < 0.05 compared to placebo group.
**p < 0.01 compared to placebo group.
+p < 0.05 compared to inhibitor group.
++p < 0.01 compared to inhibitor group
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Fig. 2.5. Effect of intravenous TGF-~ 1 treatment on blood urea nitrogen (BUN) levels in
mink with Aleutian disease. Group 1: treated with TGF-~ 1 injected 2 weeks pre-virus
inoculation (A), Group 2: TGF-~ 1 injected 8 h post-virus inoculation (B), and Group 3:
TGF-~ 1 injected 2 weeks post-virus inoculation and Group 4: TGF-~ 1 injected 3 times (2
weeks pre-, 8 h post-, and 2 weeks post-virus inoculation) (C). Animals treated with
recombinant human TGF-~ 1 (rhTGF-~ 1) at 200, 100, and I ng/kg. Inhibitor: recombinant
human latency associated peptide TGF-~ 1 (rhLAPTGF-~ 1) at 500 ng/kg. Placebo: 0.1 %
BSA in PSS. After 5 months, all animals in TGF-~ 1 inhibitor group and the placebo group
had died from AD.
*p < 0.05 compared to placebo group.
**p < 0.01 compared to placebo group.
+p < 0.05 compared to inhibitor group.
++p< 0.01 compared to inhibitor group
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Fig. 2.6. Effect of intravenous TGF-~ 1 treatment on serum interferon gamma (IFN-y)
levels in mink with Aleutian disease. Group 1: treated with TGF-~ 1 injected 2 weeks previrus inoculation (A), Group 2: TGF-~ 1 injected 8 h post-virus inoculation (B), and
Group 3: TGF-~ 1 injected 2 weeks post-virus inoculation and Group 4: TGF-~ 1 injected 3
times (2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation) (C). Animals treated
with recombinant human TGF-~ 1 (rhTGF-~ 1) at 200, 100, and 1 ng/kg. Inhibitor:
recombinant human latency associated peptide TGF-~ 1 (rhLAPTGF-~ 1) at 500 ng/kg.
Placebo: 0.1 % BSA in PSS. After 5 months, all animals in TGF-~ 1 inhibitor group and
the placebo group had died from AD.
*p < 0.05 compared to placebo group.
**p < 0.01 compared to placebo group.
+p < 0.05 compared to inhibitor group.
++p < 0.01 compared to inhibitor group.
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Fig. 2.7. Effect of intravenous TGF-B 1 treatment on serum TGF-B 1 levels in mink. Group
1: treated with TGF-B I injected 2 weeks pre-virus inoculation (A), Group 2: TGF-B,
injected 8 h post-virus inoculation (B), and Group 3: TGF-B, injected 2 weeks post-virus
inoculation and Group 4: TGF-B 1injected 3 times (2 weeks pre-, 8 h post-, and 2 weeks
post-virus inoculation) (C). Animals treated with recombinant human TGF-B 1 (rhTGFB1) at 200, 100, and 1 ng/kg. Inhibitor: recombinant human latency associated peptide
TGF-B 1 (rhLAPTGF-B 1) at 500 ng/kg. Placebo: 0.1 % BSA in PSS. After 5 months, all
animals in TGF-B, inhibitor group and the placebo group had died from AD.
*p < 0.05 compared to inhibitor group.
+p < 0.05 compared to placebo group.
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CHAPTER3
EFFECTS OF HE 2300 AND HE 2500 ON THE OUTCOME OF
ALEUTIAN DISEASE IN MINK

Abstract

Aleutian disease of mink (AD) is an immunopathological disorder of mink
induced by persistent infection with AD virus. Many breeds of mink seem to have a high
a susceptibility to AD.
Interestingly, the primary feature of AD in susceptible adult mink is a chronic,
fatal immune complex-mediated glomerulonephritis comparable to that seen in human
diseases such as systemic lupus erythematosus. Currently no therapies are available and
vaccination has been a failure; the latter exacerbates the disease.
The hypothesis to be tested in this research was that dehydroepiandrosterone-like
compounds (DHEA analogs) will inhibit or ameliorate Aleutian disease in mink. The
DHEA analog, HE2300 and HE2500, used three times weekly at 13 mg/ml, significantly
enhanced mink survival time compared to infected, untreated control mink. The severity
of the disease was lessened as determined by histopathological examination. HE2300
(3x/wk) treatment increased survival time and body weight nearly two-fold compared to
infected, untreated animals. Untreated animals had high antibody titers and high blood
urea nitrogen (BUN), creatinine, alanine aminotransferase (ALT), asparatate
aminotransferase (AST), interferon gamma (IFN-y), and circulating immune complex
(CIC) levels, suggesting immune complex deposition, a hallmark of AD. Infected,
treated animals showed a dramatic decrease in ADV-specific antibody titers. BUN,

87
creatinine, ALT, AST, IFN-y, and CIC levels. This was supported by histopathological
examination of the mink. Spleen weights of untreated animals increased by two-fold
compared to treated animals and control mink.
Another analog, HE2500, also ameliorated AD in mink when given three times
weekly at a dose of 16 ng/kg. Time to death was extended in treated mink and all other
parameters measured were similar to the uninfected control animals, although usually
mild lesions were present in kidney and liver of surviving mink in the treated group.
These findings support the hypothesis that DHEA analogs may be able to promote
an immune responses that affords protection for mink from chronic lethal AD.

Introduction

Aleutian disease virus (ADV) causes a number of interesting and completely
different disease syndromes in mink. These syndromes include decreased fertility,
abortion, acute pneumonia in kits, and chronic and persistent infections, all severely
impacting the profitability of mink farming. Interestingly, the primary feature of
Aleutian disease (AD) in susceptible adult mink is a chronic, fatal immune complexmediated glomerulonephritis comparable to that seen in human diseases such as systemic
lupus erythematosus (Bloom, 1984). Currently no therapies are available and vaccination
has been a failure; the latter exacerbated the disease (Alexandersen, 1990). For producers
who have AD in their mink, their only recourse is to kill the mink early before the coat of
the animal becomes less desirable due to AD effects, or when time to harvest the pelts
comes to gamble that the disease will not afflict a significant portion of their animals.
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Therefore, a need exists to develop a modality that can boost the susceptible animals'
immune responses in an appropriate manner to allow them to survive the disease.
Despite intensive studies, the mechanism by which ADV induces a severe
disorder of immune function and establishes a chronic, persistent infection remains
unclear. It is also not well established whether inbreeding of the animals may be part of
the problem. The mink have been so extensively inbred that certain varieties (e.g.,
sapphires, a.k.a. Aleutian mink) may not be immunocompetent.
Recently, several studies have been done to understand how ADV disturbs host
immune function (Aasted and Leslie, 1991; Mori et al., 1991; Kanno et al., 1992). From
these studies, it has become apparent that the initial target for ADV replication is
probably the macrophage found in the medullary sinuses of the lymph nodes of infected
mink (Kanno et al., 1992). Secondary targets are B lymphocytes, circulating
macrophages and follicular dendritic cells. The phenotype of AD is characterized by
extreme hypergammaglobulinemia caused by the production of non-neutralizing antiADV (Alexandersen, 1990) and polyclonal antibody production, including anti-ADV
DNA antibodies (Hahn and Hahn, 1983). Subsequently, plasmacytosis (Porter et al.,
1980), arteritis (Porter et al., 1973), as well as immune complex-mediated
glomerulonephritis, develops. These features suggest that some step in B cell
development and/ or maturation is overstimulated by ADV infection (Kanno et al., 1992).
Several theories have been advanced to account for the hypergammaglobulinemia
described above (Kanno et al., 1992). Among them are i) cytokines are produced in
response to ADV infection of target cell macrophages that enhance B cell proliferation
and maturation; ii) viral components (e.g., structural proteins) might directly stimulate B

89
cell development and clonal expansion; iii) abnormal antigen presentation by infected
macrophages might disturb subsequent B cell development and proliferation.
In support of the first hypothesis are the findings of Bloom et al. ( 1994) that
macrophages produce interleukin-6 (IL-6) in antibody-dependent ADV infection. In
addition, IL-6 mRNA can be detected in the mesenteric lymph nodes of ADV-infected
mink. Perhaps not coincidentally, human diseases that are characterized by
hypergammaglobulinemia are also associated with high levels of IL-6 production (e.g.,
Castleman's disease). Thus, AD may be a virus-induced cytokine disorder; a syndrome
of chronic, inappropriate production of IL-6 and perhaps other cytokines (Bloom et al.,
1994).
A pertinent observation for the treatment of AD in mink is that an attenuated
vaccine only enhances the disease, leading to an especially extreme B cell hyperplasia,
while immunosuppressive therapy has been shown to somewhat ameliorate the severity
of disease, e.g., preventing Aleutian disease lesions (Cheema, et al., 1972). These
therapies have only produced marginal results. One of the compounds chosen,
levamisole, does not directly modulate the B cell function of producing of antibody
(Amery and Harig, 1984). The other compound, isoprinosine, actually enhances B cell
antibody production in the presence of pokeweed mitogen (Tsang et al., 1984), perhaps a
less than desirable effect in AD where over-production of antibody leads to fatal disease.
The ~-androstene steroids form a subgroup of steroids that up-regulate immunity,
increases resistance against lethal infection and lethal radiation, and mediate a rapid
recovery of hematopoietic precursor cells after radiation injury. In vivo, the ~androstenes increase the levels of the Th 1 cytokines such as IL-2, IL-3, IFN-y; they also
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counteract hydrocortisone immune suppression, and function in the maintenance of the
Th 1/ Th2 balance and immune homeostasis.
There is considerable evidence for an immunomodulatory role for a cytokine,
dehydroepiandrosterone (DHEA), ~-androstene. It both potentiates and inhibits various
functions of the immune system in its regulatory role, depending on when and where it
is expressed (Loria, 2002). However, its potent effects on immune cells in vitro are
reflected in the various effects it has in various animal model systems, strongly
suggesting an important role in immune disorders such as autoimmune disease (Derynck
and Choy, 1998). DHEA, one of these ~-androstenes, has been shown to have
immunomodulating effects in several experimental infections involving viruses and
protozoans (Rasmussen et al., 1991; Mulder et al., 1992; Uozumi et al., 1996; Loria and
Padgett, 1998). In HIV infections, 17a-bromoepiandrosterone (a-epi-Br), an analog of
DHEA, may shift cytokine production to a Th 1 response and increase circulating
activated immune effector cells (Freilich et al., 2000). This activity appeared not to be
androgenic, since the compound only bound weakly to the androgen receptor. In
contrast, the 17a-epimer of androstenetriol inhibits proliferation and mediates apoptosis
in tumor cells of murine and human origin (Loria, 2002). The antiproliferative functions
of 17a-androstenediol are not dependent on either the estrogen or androgen receptors.
Thus, DHEA and its analogs may be able to promote Thl cytokine-type responses
that could afford protection for mink from chronic lethal AD. Therefore, we attempted
to develop several approaches for treating experimental AD using epiandrosterone
analogs. We tested the hypothesis that treatment of AD-infected mink with TGF-~ or
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epiandrosterone analogs would ameliorate the development of the AD as shown by an
enhanced survival time and lessened other AD parameters in the animals.

,

Materials and Methods

Animals
Unmated or non-parous 1-year-old female mink weighing 600-1000 g were used.
These mink were obtained from the Windy Peaks ranch facility (Franklin, ID). This
facility has been free of AD for about 6 years as determined by serological testing and
pathology results. All animals were tested for AD by counter-immune-electrophorsis
prior to admittance to animal research facility.
Mink were fed a one-time daily ad libitum diet (approximately 100 g) with a fishbased diet formulated for optimal growth, pelt quality, and seasonal variations in
nutritional needs by the Mink Farmer's Cooperative of Utah.
Blood for analysis was obtained by toe clip, and when mink were sacrificed, they
were euthanized by carbon monoxide inhalation in a sealed plexiglass chamber in an
aerated room.
Animals were held to up to 8 months. Signs of disease were measured monthly
by analyzing serum samples using antibody, blood urea nitrogen, interferon gamma, and
circulating immune complex assays. Confirmation of disease was measured by
histopathology examination of kidney, liver, and spleen and by detection of viral DNA in
mesenteric lymph nodes. In addition, animals were monitored monthly to determine
weight loss or gain, weight loss being a symptom of AD.
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Study Design
Five mink received 16 ng/kg of HE2300 (~-androstenetriol (~-AET); 5androstene-3~-7~-triol; Hollis-Eden pharmaceuticals, San Diego, CA) once per week, 17
animals received 16 ng/kg of HE2300 three times per week and five animals were
injected with 16 ng/kg of HE2500 (fluasterone [FLST]; 16a-fluoro-5-androsten-17-one;
Hollis-Eden pharmaceuticals, San Diego, CA) three times per week. In addition, 17
animals received vehicle three times per week. All treatments were injected
subcutaneously into the nape of the neck of the mink. In addition, six animals only
received virus (Table C. l ). All animals exposed to virus were injected with virus
intraperitoneally and received 5 X 105 fluorescent focusing units of ADV of mink (Strain
Utah I). Five animals did not receive virus or any treatment. Treatment began 8 h after
virus exposure.

Cell
The macrophage cell line RAW 264.7 was obtained from American Type Culture
Collection (Manassas, VA, USA.). The cells were routinely passaged with in Dulbecco's
modification of minimal essential medium (GIBCO Invitrogen Corporation, Grand Island,
NY, USA) containing 4000 mg/L glucose. The medium was supplemented with 4 mM
L-glutamine (GIBCO Invitrogen Corporation), 0.1 mM sodium pyruvate (GIBCO
Invitrogen Corporation), 0.15% sodium bicarbonate and 10% fetal bovine serum
(Hyclone Laboratories, Logan, UT).

Counter Current lmmunoelectrophoresis
CEP was done according to the manufacturer's instructions using commercially
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available reagents (United Vaccines, Madison, WI). Briefly, the samples were run on 80
X 100 mm agarose gels into which wells had been punched. Known antigen plus serum
dilutions from the infected animal were placed in wells in apposition to one another. The
gels were exposed to electrical current at a constant 40 volts for 1 h. Titers of antibody
for each treatment were calculated by taking the inverse of the last dilution at which
precipitation was detected using the last available serum prior to death. These titers were
then averaged for each treatment group.

Interferon-y Bioactivity Assay
This assay was used as an indicator of a Thl cellular response. A nitric oxide
production bioassay for interferon-y was used to assay for interferon-yin serum samples
(Kim and Son, 1996). RAW cells, a murine macrophage cell line (American Type
Culture Collection, Manassas, VA), were seeded at 1 X 105 cells per well in a 96-well
flat-bottomed plate (Coming Costar, NY) and incubated at 37°C for 6 h. The cells were
then exposed to a known interferon stimulator or a filtered serum sample for 24 h at
37°C. Nitric oxide produced in response to interferon induction in the cells was detected
by the addition of dimethyl-a-naphthylamine, yielding a red color. Absorbances were
detected spectrophotometrically at a wavelength of 540 nm. Absorbances were converted
to nitrite concentration (µ,M) using a standard curve for each assay done.

Circulating Immune Complex (CIC) Assay
This serum-based assay was done by following the instructions of a commercially
available CIC kit (APLPCO Diagnostics, Windham, NH) to quantitate the amount of CIC
found in each mink serum sample.
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CICs normally activates complement when they are formed in the host and are
normally cleared by phagocytosis. The component of the complement systetn that binds
these complexes is complment-lq (Clq). For this assay Clq was used to capture any
immune complexes found in serum samples. CIC binding to Clq was detected using an
alkaline phosphatase conjugated Protein A, which binds to the Fe region of IgG, the
predominate antibody associated with immune complexes (Wehler et al., 1981).
Dilutions of mink sera (beginning at 1:50 dilution) or standards and controls were
incubated with human Clq pre-adsorbed onto microtiter wells for 1 h at room
temperature. The detection protocol of the kit was then followed. Absorbance at 405 nm
was read. CIC concentrations detected in various mink sera were calculated from
standard curves generated using the positive controls provided in the kit.

Blood Chemistry Evaluations
Blood chemistry profiles of sera were determined using a calibrated blood
chemistry analyzer at Logan Regional Hospital (Logan, UT). A 15 parameter protocol
was used and included detection of Ca+, Na+, K+ and

er levels.

Sera were also tested for

the serum levels of the following: urea/nitrogen, creatinine, albumin, aspartate and
alanine aminotransferases, total bilirubin, alkaline phosphatase, lactate dehydrogenase,
glucose, and CO 2 •

Polymerase Chain Reaction Detection of Viral DNA
DNA was extracted from mesenteric lymphoid tissue using the DNeasy kit
(Qiagen, Valencia, CA). For the PCR reaction the primers used were those described by
Jackson et al. (1992). The reactions consisted of the following components: 49.5 µJ of
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double distilled water. 0.25 µ,M concentration of each primer, 0.2 mM of all four
dexyribonucleotide triphosphates, 50 mM KCL, 10 mM Tris-HCl (pH 8.8), 1.5 mM
MgCl2, 0.2% Triton X-100, 2.5 units Tag DNA polymerase (Promega) and dilutions of
DNA from the samples. For each gel run, there was a positive control, negative control
and reagent control. PCR amplification was carried out using a thermal cycler in the
following manner:
Denaturation: 95°C for 1 min
Primer annealing: 55°C for 1 min
Primer extension: 72°C for 2 min
Thirty cycles were performed. After amplification, samples were analyzed on a
1.0% agarose gel in TAE buffer (Ausubel et al., 1987). Bands were visualized with
ultraviolet light and photographed using Polaroid film.

Histopathological Examinations.
Upon the death of each mink, either from AD or when sacrified the kidneys and
liverwere removed and tissues from each were sectioned, fixed and then stained with
hematoxylin and eosin. Typical pathological findings for AD included thickened
mesangium in the glomeruli with homogenous eosinophilic material (membranous
glomerulopathy), detection of multifocal infiltrates of plasma cells and lymphocytes in
the interstitium of the kidney cortex (interstitial nephritis) and also in the medulla,
multiple convoluted tubules containing eosinophilic material or granular casts, occasional
mineralization basement membranes, and portal areas of the liver with varying numbers
of infiltrated plasma cells and lymphocytes (hepatitis) randomly dispersed among the
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hepatocellular cords. Samples were coded and sent to a board certified pathologist (Utah
State Veterinary Diagnostic Laboratory, Logan, UT), who examined the samples for the
above-defined pathology; abnormalities were scored as mild (+), moderate (++), and
severe (+++). Samples with the pathology described above were considered positive for
AD.

Statistical Analysis
Statistical significances were determined by analysis of variance and Student's ttest where appropriate. Standard deviations (SD) were determined for all mean values.
Log rank test was for distribution of survival equality in the two groups. In other
words, log rank test was to test statistical significance of survival environment each
infected-treated group compared to infected-untreated. Statistically, F-value and p-value
of statistical significance were often reported.

Results

Effects of HE2300 and HE2500 Treatment on Physiological and Physical
Parameters of Mink exposed the Aleutian Disease Virus

Survival Time
Mean and median survival times in the normal control group was eight months.
All infected animals receiving no treatment presumably died from AD, since they all
exhibited pathogical lesions consistent with AD. The mean and median survival times in
the infected, untreated group was 3.8 and 4 months, respectively, which was significantly
(p < 0.001) reduced compared to the 8 months survival time of the normal control group
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(Fig. 3.1). Sixteen percent of the animals in the virus-infected group survived 4 months.
'

The null hypothesis that there was no difference in survival experience between the two
groups was rejected. The mean and median survival time in the infected vehicle-treated
group was 4 months in both cases, again a significantly reduction in survival time
compared to control (log rank test, p < 0.01). Forty-seven percent in the vehicle group
survived to 4 months of age. Only one animal survived 8 months in the vehicle-treated
group exposed to virus.
The mean and median survival times in the HE2500 (treated three times per
week) group was 6 and 8 months, respectively. Sixty percent of the animals in this group
survived to 4 months of age, compared to the vehicle and untreated virus control groups.
However, one animal in this group apparently did not die from AD; the lesions were not
consistent with ADV pathogenesis. Excluding that animal, the survival rate was 75% and
the mean time to death was 7 months that is statistically different from vehicle and virus
controls. Mink treated with HE2300 one time per week afforded the mink much less
protection against lethal AD. These animals had a mean survival time of 4 months and
only one animal (20%) in that group survived the 8 months duration of the experiment.
By contrast, the mean and median survival time in HE2300 (treated three times per week)
group was 7 and 8 months, respectively. Fifty-two percent in this group survived 4
months, which was statistically significant compared to placebo-treated controls (p <
0.05, log rank test).
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Weight Gain
Mink were weighed prior to any treatment and that weight was designated "preexposure weight." The post-virus exposure weights represent the mean weight of
animals in each treatment group just prior to death or sacrifice. The mink which were
untreated and not exposed to virus (normal control animals) had significant weight
increases relative to the infected untreated animals (p < 0.01, Fig. 3.2). Mink that were
exposed to virus or virus plus vehicle had significant weight losses when compared to the
average pre-exposure weights of the same animals. Animals exposed to virus and then
treated with any of the treatment regimens gained weight similar to that of the normal
controls and gained a significant amount of weight relative to vehicle-treated virus
exposed mink and infected untreated mink (p < 0.01).

Histopathological Findings
Histopathogical examination of the dying or sacrificed animals exposed to ADV
revealed the following results. Twenty-five percent of the mink treated with HE2500
appeared to have no lesions associated with AD, while the remaining mink did exhibit
lesions consistent with AD ranging in severity from mild to severe (Table 3.1). One
animal in this group had particularly severe lesions and survived 5 months; the remainder
survived the entire 8 months of the experiment (Table 3.2).
All animals treated with HE2300 one time per week had lesions indicative of AD.
When treated with same compound three times per week, two animals did not exhibit
AD-like lesions, whereas 10 had a severity score of+ and five had a severity score of++.
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No lesions specific for AD were detected in two animals treated with vehicle. However,
four animals had lesions classified as mild and eight had lesions scored as moderate to
severe. As expected, all untreated, virus-exposed mink demonstrated pathology
attributable to AD.

Serum Levels of Ions
Maintaining of proper ion levels the serum is extremely important for homeostasis.
When these levels are abnormal, they often reflect problems with absorption, usually at
the level of the glomerular and tubules of the kidney. Since a hallmark of AD is
glomerulonephritis and renal dysfunction, the serum levels of sodium, calcium,
potassium, and chloride ions were monitored throughout the duration of the experiment.

Mink that were infected and not treated or treated with placebo showed
significantly (p < 0.05) increased levels of K+, Na+ and
treatment groups (Fig. 3.3). These levels of

er relative to animals in other

K+,Na+ and er were also elevated when

compared to levels in each animal prior to infection. Serum Ca +2 levels in the placebo
and untreated groups dramatically dropped during the experiment and were significantly
different from the other groups of mink. In treated animals, the levels of the ions
remained relatively constant throughout the duration of the experiment.

Serum Levels of Liver Enzymes
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are
enzymes produced abundantly in hepatocytes and their release into the serum indicates a
reduction in liver function, although diet (mink diet was rich in fish offal containing
amines) may influence these enzyme levels to some extent. In mink treated with HE2500
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and the one dose of HE2300 (three times per week), the serum levels of these two
enzymes were not significantly different from the normal untreated, uninfect'ed controls
(Fig. 3.4). However, the virus-infected mink receiving vehicle or no treatment had much
higher (p < 0.05) serum levels of the two liver enzymes compared to the drug-treated
infected animals.

Serum Levels of Nitrogenous Compounds
Detectable levels of urea, creatinine or other nitrogenous compounds in serum are
usually indicative of damage to the kidneys, probably at the level of readsorption through
the tubules. In mink treated with HE2300 (three times per week) and HE2500, the levels
of urea/nitrogen were similar to the normal uninfected, untreated controls (Fig. 3.5).
However, the levels of those metabolites in virus-infected mink receiving vehicle and in
the untreated group of mink were significantly higher (p < 0.05) than drug-treated and the
normal control groups.
High serum creatinine levels are a sign of severe renal impairment, but such levels
were not found in the serum at any significant amounts above or below the normal
control group for the HE2300 (three times per week) and HE2500 group (Fig. 3.5).
However, the levels of creatinine in virus-infected mink receiving vehicle and infected,
untreated group were significantly higher (p < 0.05) than thedrug-treated and normal
control group.
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Effects of HE2300 and HE2500 on Viral and Immunological
Parameters in Mink Infected with ADV

Virus Levels
Viral DNA was detected in the mesenteric lymph nodes of exposed mink by PCR
amplification and gel analysis from samples taken as soon after death as possible or after
sacrifice. Twenty percent of the mink treated with HE2500 were found to have viral
DNA, 40% treated with HE2300 given one time per week were also positive for viral
DNA and 18% of the mink treated with HE2300 three times per week were positive
(Table 3.3). In the vehicle control animals, 71 % were positive and 83% of the mink
exposed to virus only were also found to be positive for viral DNA. Only four mink
receiving HE2300 treatment three times per week were positive for viral DNA and this
was significantly lower than those infected and treated with placebo (p = 0.003).

Specific ADV Antibody Levels
High titers of antibody (>512) are often associated with progressive chronic AD
(Bloom et al., 1994). Serum was analyzed for ADV-specific antibody by CEP assay. In
mink treated with HE2500, the average titer upon death of the animal was 666, for mink
treated with HE2300 one time per week, 339 and for mink receiving HE2300 three times
per week, 337 (Fig. 3.6). In contrast, the average titers in vehicle-treated mink and in
infected, but untreated mink were significantly higher, 1365 and 1536, respectively (p <
0.001). All placebo animals were dead after 5 months, generally due to complications
from AD.

102

Circulating Immune Complexs (CIC) Titers
One of the hallmarks of AD pathology is the destruction of kidney tissue due to
deposition of CIC in the kidney and subsequent complement-mediated destruction of the
basement membrane of kidney tubules. Mink that were infected with virus and not
treated or received vehicle had much greater CIC levels in their serum than the treatment
group receiving HE2500 and significantly higher levels than those mink receiving either
dose of HE2300 (p < 0.01, Fig. 3.7). Virus-infected mink that were not treated also had
substantially higher levels of CIC than any of the compound treatment regimens.

Serum Gamma Interferon (IFN-y) Activity
Mink treated with HE2300 given three times per week had NO levels that were
much less than were those detected in vehicle-treated mink or in virus-infected mink
receiving no treatment (p < 0.01, Fig. 3.8). In addition, the mink treated with HE2500 or
HE2300 given one time per week, the NO levels were significantly reduced as well (p =
0.0345,and 0.007, respectively). Levels of NO with all drug treatments were very similar
to the levels detected in uninfected, untreated mink.

Splenomegaly
Splenomegaly is a reflection of an active infection or any number of abnormalities
including hypergammaglobulinemia, liver disorders and AD (Bloom et al., 1994). In
mink with AD this is probably due the prodigious production of antibody (sometimes 100
mg/dl) in response to virus infection. In this experiment, mink that were infected with
ADV had much larger spleen weights than did control mink or mink treated with HE2500
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or HE2300 (Fig. 3.9). In addition, the average spleen weight in untreated mink exposed
to virus was significantly heavier than in unexposed, untreated mink (p < 0.01).

Discussion

Previous preliminary experiments run by us with HE2300 had indicated that
treatment of ADV-infected mink three times per week increased the survival time of
those mink (data not shown). The current experiments were done to verify those initial
findings, as well as to evaluate a less frequent dosing regimen and to evaluate a new
compound, HE2500, for efficacy in this immune complex disease model.

HE2500 3x/wk

The effects of treatment on surviving animals were assessed using the parameters
discussed above. Mink treated with HE2500 had a significant reduction in weight gain
compared to control mink (p < 0.001), although all surviving animals did gain some
weight throughout the experiment (Table 3.2). Serum levels of nitrogenous compounds
and liver enzymes were elevated, although not significantly different from what was
detected in normal (uninfected/ untreated) mink. Only one animal in this group had no
pathology attributable to AD, even though virus was not detected in any of the surviving
animals (Table 3.4). Relative to the sole surviving animal in the vehicle-treated group,
the ADV-specific antibody titers in the HE2500-treated animals were much lower as
were the levels of CIC (p < 0.001), the latter being no different than those levels detected
in the control animals. Interferon-y activity was also comparable to the untreated,
uninfected control animals.
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A three times per week dosage regimen of HE2500 at 16 ng/kg dosage was
effective in treating ADV-infected mink. The compounds appeared to delay the
progression of the disease.

HE2300 Ix/wk
One animal in this treatment group survived eight months. This mink did not
significantly gain weight compared to the control mink, but unlike the surviving animal
in the infected vehicle-treated group, it did not lose weight (Table 3.2). This animal had
very definite lesions consistent with AD, although no virus was detected in the
mesenteric lymph nodes (Table 3.4). The liver enzyme levels in the serum were quite
elevated compared to the uninfected controls, but the serum levels of nitrogenous
compounds were only slightly elevated compared to controls (Table 3.2). The antibody
titer specific for ADV was much lower than that titer in the surviving mink from the
vehicle-treated group and typical for animals exposed to disease that are long-term
survivors (Table 3.4). The level of circulating immune complexes was commensurate
with the low ADV-specific antibody titer and equivalent to that found in the control
animals. Interferon-y activity was also similar to that detected in the uninfected control
animals. Despite the favorable physiological and immunological outcomes, this mink did
sustain moderate damage to the kidney and liver, which consisted of patchy membranous
glomerulopathy, some multifocal interstitial nephritis, and hepatitis with infiltration of a
few lymphocytes and plasma cells in the portal areas of the liver.
A one time per week regimen of HE2300 at 16 ng/kg dosage failed to protect
most mink from lethal chronic AD.
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HE2300 3xlwk
The mink in this treatment group also had significant reductions in weight gain
(Table 3.2); five of the animals lost weight (10-140 g), although not as severe as the
weight loss in the vehicle-treated animal, which lost half its original body weight (-450
g). The remaining animals maintained their weight or gained weight (0-110 g). Only
two mink in the HE2300 group did not have demonstrable AD lesions in the kidney and
liver, while most remaining mink had moderate lesions in the kidney and liver with one
animal having severe lesions. The blood urea/nitrogen serum levels were elevated
relative to the normal (uninfected, untreated) controls, although the creatinine levels were
similar to the normal controls (Table 3.2). Serum levels of the livers enzymes were
elevated in this treatment group, although this was statistically not significant due to the
variability in these measurements. Spleen weights were near normal as were the levels of
CIC (Table 3.4). ADV specific antibody titers in this group were again typical for
animals surviving a potentially lethal exposure to ADV (<512). The large, pronounced
level of interferon-y activity detected in the surviving vehicle-treated mink was not
detected in the HE2300-treated mink and was actually no greater than those levels found
in the uninfected control group.
HE2300 given three times per week at 16 ng/kg was the most effective means of
treating ADV-infected mink. The compounds temporarily halted or slowed down the
progression of the disease.
The data in the current study support the idea that a dosing regimen of three times
per week with HE2300 significantly increases mink survival time after exposure to ADV.
Nevertheless, substantial numbers of mink still succumbed to the chronic effects of ADV
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exposure. All parameters measured indicated that HE2300, using the three times per
week dosing regimen, was not only effective in delaying time to death, but that the
severity of the disease was lessened within the time period studied in that particular
treatment group. The parameters measured in a subset of the HE2300-treatment group,
surviving mink, were all comparable to those measured in the uninfected control group
with two exceptions, the pathology detected and weight gain. In the survivor group, mild
to moderate lesions were still found despite treatment and weight gains were less, lending
credence to the supposition that treatment may only delay the time to death and
appearance of severe lesions, but not permanently alter the course of a chronic AD
infection.
Similar results were seen with the HE2500 treatment regimen. Time to death was
extended substantially and the measured parameters in surviving mink were similar to the
control group, but again pathology attributable to AD was still detected in the kidneys
and liver of the treated animals.
Interestingly, a parameter that seemed predictive of a negative outcome was the
presence of high levels of interferon-y, a Thl cytokine. Interferon-y has also been shown
to correlate with pathogenesis in another immune complex-mediated disease, systemic
lupus erythematosus (Kuroiwa and Lee, 1998). In knock out mice, interferon-y
apparently was an important cytokine in amplifying the local immune responses of lupus
nephritis. Infiltrating mononuclear cells exerted their effects on resident renal cells
through secretion of soluble factors and apparent promotion of cell-to-cell contact. This
scenario may not be the case with AD because in AD large numbers of lymphocytes are
found at the lesion and not macrophages/monocytes.

Instead, the high interferon-y levels
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could activate localized cytotoxic T cells by stimulating expression of MHC class I
antigen cells on putative target cells (De Maeyer and De Maeyer-Guignard, 1998), for
example, cells of the basement membrane coated with immune complexes. The latter
scenario may correlate with our findings that infiltrating lymphocytes are often at the site
of lesions associated with AD.
From the data shown in this report, it is readily apparent that a three times per
week regimen of either HE compound was most effective in treating ADV-infected mink;
the one time per week regimen failed to protect most mink from lethal chronic AD. The
experimental design did not allow the determination of whether the compounds
ameliorated the severity of the pathogenesis permanently, whether the lesion damage was
reversible or irreversible, or if the compounds "cured" mink of the disease. However, the
lack of detection of viral DNA and the reasonably low levels of specific ADV antibody
and circulating immune complexes all suggest that the virus was cleared, thus eliminating
a continual stimulator of what appears to be type III hypersensitivity response. This
would support the notion that at the very least, HE compounds can temporarily halt or
slow down the progression of the disease.
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Table 3.1
Summary of histopathological findings of AD-infected mink subcutaneously treated with HE2300 or HE2500.

No. of animals displaying
Pathology Severity Scores

Percent Animals Positive
for AD Pathology

Treatment

0

+

++

+++

+

HE2500a 3X/wk*

1

2

0

1

75

HE2300b lX/wk

0

3

2

0

100

HE2300 3X/wk

2

10

5

0

91.5

Vehicle 3X/wk**

2

4

7

1

91.5

Untreated

0

1

5

0

100

Normal control

5

0

0

0

0

aFluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative).
b~-androstenetriol (~-AET; 5-androstene-3~-7~-triol; natural androsten hormone).
*One animal from this group died from bacterial infections or other causes not attributable pathology.
**Three animals from this group died from bacterial infections or other causes no attributable AD pathology.
+: mild, ++: modulate and +++: severe

N

Table 3.2
Summary of selected physical and physiological parameters eveluated in HE2300- or HE2500-treated mink infected with ADV
and surviving 8 months.

Pathology
Severity
Scores (-/+)

Blood Urea
Nitrogen
(mg/di± SD)

Treatment Group

Survivors

Average
Weight
(g ± SD)

HE2500" 3X/wk

3/5

1113 ± 35*

1/2

22.7±17.6

HE2300b IX/wk

1/5

1060 ± O*

0/1

22±0

HE2300 3X/wk

9/17

1103 ± 34*

2/7

Vehicle 3X/wk

1/17

Untreated

0/5

Normal control

5/5

35.9 ± 33.2*

0/lc

17 ± 0

0

0/0

0

1360 ± 204

5/0

14.4 ± 4.53

550±0

Serum
Creatinine
(mg/dl ± SD)
0.4 ± 0.3*
0.8 ±0
0.8 ±0.3
0.7±0
0
0.7 ± 0.11

Serum Aspartate
Serum Alanine
Aminotransferase Aminotransferase
(U/L± SD)
(U/L ± SD)
118.1 ± 111.4*
243 ± O*
170.3 ± 109.3*

91.7 ± 51.3*
162 ± O*
155.7 ± 114.9*

426 ± 0*

307 ± 0*

0

0

42 ± 2.13

42 ± 2.13

aFluasterone (FLST; 16a-fluoro-5-androsten-17-one;
synthetic androstene derivative).
bp-androstenetriol (P-AET; 5-androstene-3P-7P-triol; natural androsten hormone).
cHistopathological investigation revealed moderate to severe lesions indicative of AD in kidneys and liver (severity score=++).
*p < 0.01 compared to normal control group.

-

vJ

Table 3.3
Detection of viral DNA in mesenteric lymph nodes of AD-infected mink treated subcutaneously with HE2300 or HE2500.

Post-Exposurea

Pre-Exposure

Treatment Group

Presence of Viral
DNA (Positive/total)

Presence of Viral
DNA (Positive/total)

Percent Animals Positive
for Viral DNA

HE2500b 3X/wk

0/5

1/5

20+

HE2300c IX/wk

0/5

2/5

40

HE2300 3X/wk

0/17

4/17

18+

Vehicle 3X/wk

0/17

12/17

71*

Untreated

0/6

5/6

83*

Normal control

0/5

0/5

0

Represents the lymph node available prior to death or sacrifice of the animal.
b Fluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative).
c ~-androstenetriol (~-AET; 5-androstene-3~-7~-triol; natural androsten hormone).
*p ~ 0.01 compared to normal control group.
+p ~ 0.01 compared to infected, vehicle and untreated groups.
a

Table 3.4
Summary of selected viral, serological and immunological parameters evaluated in HE2300- or HE2500-treated mink infected
with ADV and surviving 8 months.

Average
spleen weight
(g ± SD)

Average
CEP titer
(± SD)

Average
CIC titer
(µg E/ml ± SD)

Treatment Group

Survivors

Presence of
viral DNA
(-/+)

HE2500a 3X/wk

3/5

3/0

2.2 ± 0.8

181 ± 129

5.6 ± 1.5

HE2300b lX/wk

1/5

1/0

2.9 ±0

256± 0

2.1 ± 0

HE2300 3X/wk

9/17

9/0

2.4 ± 0.6

213 ± 140

2.6 ± 0.1

Vehicle 3X/wk

1/17

0/1

5.8 ± O*

Untreated

0/5

0/0

0

0

Normal control

5/5

5/0

2.1 ± 0.5

0

2048 ± O*

61.6+0*
0
3.8 ±2.2

IFN-y bioactivity
assay average Nitrite
serum concentration
(µM± SD)
13.8 ± 3.5
7.8 ± 0
11.8±3.7
48.3 ± O*
0
8.6 ± 1.6

aFluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative).
b0-androstenetriol (0-AET; 5-androstene-30-70-triol; natural androsten hormone).
*p < 0.01 compared to normal control group.
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Fig. 3.5. Effects of subcutaneous HE2500 and HE2300 treatment on serum levels of
blood urea nitrogen (A) and creatinine (B) in ADV-infected mink. All placebo animals
were dead after 5 months, generally due to AD.
*p < 0.05, **p < 0.01 and ***p < 0.001 compared to normal control group.
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CHAPTER4
SUMMARY AND CONCLUSIONS

ADV Immunological Response

When ADV is first present in the body, both Thl and Th2 type of immune
responses are activated. As the infection becomes chronic, there is a shift from the Thl
to a Th2. For these studies, the immunological response to AD is overwhelmingly
humoral (hypergammaglobulinemia) and mediated by Th2 type cytokines (especially
high levels of IL-6). Based on these findings, AD may be a virus-induced cytokine
disorder; it is a syndrome of chronic, inappropriate production of IL-6 and perhaps other
Th2-type cytokines.
A Th 1 immune response is characterized by an inflammatory response with the
release of IFN-y, IL-2, IL-12, TNF-a, ~' and activation of macrophages and induction of
CDS+ cytolylic T-cells. It is responsible for clearance of viral and intracellular infections.
A Th2 immune response can also mediate an anti-inflammatory responses, but is
better characterized by the stimulation of antibody production by B-cells. It does not
promote tissue damage as do Thl cells, which release IL-3, 4, 5, 6, and 10. Th2
predominance leads to the suppression of Th 1 cytokines such as IL-12 and IFN-y.
Thus, if one could modulate the immune response in AD-infected animals to
largely cell-mediated response with Thl type cytokines, the severity of AD might
diminished or perhaps even prevented. Previous immunemodulation studies of AD using
immunosuppressive therapy has shown slight amelioration of the severity of disease.
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Two compounds of interest have been shown to modulate the immune system
towards a Th 1 response: TGF-~ 1 and DHEA; with that in mind we evaluated the effects
of exogenous human TGF-~ 1 and two DHEA analogs on their ability to diminish the
severity of AD mink and enhance survival time in mink infected with AD.

Ameliorating Aleutian Disease in Mink by Treatment
with Human rTGF-~ 1

Potential Mechanisms of Inhibition
(1)

TGF-~ 1 may be able to promote Thl cytokine-type response that could afford
protection for mink from chronic lethal AD.

(2)

Potent effects on immune cells in vitro are reflected in the various effects TGF-~ 1
has in various animal model systems; Inhibition by TGF-~ 1 is very important in
mediating immune disorders such as autoimmune disease.

(3)

A finding pertinent to the potential immunotherapy of AD is that exogenous
administration of TGF-~ 1 in vivo markedly depresses inflammatory and
immunological responses (e.g., it delays the onset of experimentally induced
arthritis in mice, a disorder involving immune complexe).

(4)

TGF-~ 1 modulation of Thl and Th2 immune responses. TGF-~ 1 also regulates
the primary antigen presenting cell (it is activated T lymphocyte responses that
are responsible for correct processing of virus antigen). Thus, it has a regulatory
role in the differentiation of T cells (expression of CD8+ ). It also, it strongly
promotes the generation of Thl cells. Thus, it is conceivable that TGF-~ 1 could
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elicit a Thl response adequate enough to ameliorate AD by inducing appropriate
processing of AD antigen.
(5)

TGF-~ 1 inhibition of to B cell proliferation. TGF-~ 1 inhibits B cell proliferation
and is able to induce apoptosis (programmed cell death) in B cells in addition to
reducing the secretion of immunoglobulin from activate B cells. These
mechanisms suggest that TGF-~ 1 may be able down-regulate a B cell hyper
response such as seen in mink with AD.

(6)

TGF-~ 1 inhibition of antibody class switching. Early hematopietic growth and
differentiation alters B cell lg production and class switching, and inhibits mast
cell, thymocyte, B cell and T lymphocyte proliferation

Summary of Results Nine Months (266 days)
after Exposure to ADV
(1)

TGF-~ 1 treated animals had an increase of nearly two-fold in survival time
compared to infected placebo-treated or untreated animals (Table B.1).

(2)

TGF-~ 1 treated animals had an increase of nearly two-fold in body weight
compared to infected untreated animals (Table B.2).

(3)

TGF-~ 1 treated animals showed a dramatic decrease in ADV-specific antibody
titers compared to placebo-treated or untreated infected animals. BUN, IFN-y,
and CIC levels were well within normal parameters (Table B.3, B.4, and B.5), .

(4)

TGF-~ 1 treated animals had a two-fold increase body weight compared to infected
placebo-treated or untreated animals, although they lost weight compared to their
initial weight.
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Conclusions: Analysis of the Mink Treated with TGF-/J1
(1)

TGF-~ 1 at 100 or 200 ng/kg regimen was most effective in treating ADV-infected
mink; both doses appeared to delay the progression of the disease (Table B.6 and
B.7).

(2)

TGF-~ 1 at 1 ng/kg regimen failed to protect most mink from lethal chronic AD.

(3)

Treatment with LAPrhTGF-~ 1-inhibitor at 500 ng/kg regimen resulted in high
physical, physiological and immunological parameter levels in the AD-infected
mink; the kidneys were damaged by immune complex deposition, a hallmark of
AD.

(4)

These findings support the hypothesis that TGF-~ 1 treatment of mink by inguinal
vein injection can ameliorate AD in mink.

Effects of HE2300 and HE2500 on the Outcome of
Aleutian Disease in Mink

Potential Mechanisms of Inhibition
(1)

DHEA, an epiandsterone increases the levels of Thl cytokines, IL-2, IL-3, and
IFN-y and counteracts hydrocortisone-mediated immune suppression that could
afford protection for mink from chronic lethal AD.

(2)

HE2300 (~-ABT), a natural androstene, up-regulates immunity, which increases
resistance against lethal infection and lethal radiation, and mediates a rapid
recovery of hematopoietic precursor cell after radiation injury

(3)

HE 2300 protects the host from lethal infection by DNA or RNA viruses such as
herpesvirus type 2, coxsackie virus B4, influenza, and arthropod borne viruses. In
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addition, mortality from a lethal challenge of human enteric virus was reduced by
50% when animals were treated with HE2300.
(4)

DHEA has been shown to have general immunomodulating effects in
experimental infections involving viruses.

(5)

DHEA shifts cytokine production to a Thl response and increases circulating
activated immune effects or cells in HIV infections.

Summary of Results Eight Months After Exposure to ADV
(1)

HE2500 and 2300 (3x/week) treatment increased survival time and body weight
nearly two-fold compared to infected, untreated animals (Table C.2).

(2)

HE2500 and 2300 (3x/week) treated animals showed a dramatic decrease in
ADV-specific antibody titers, and BUN, creatinine, ALT, AST, IFN-y, and CIC
levels werelowered in treated animals (Table C.3, C.4, and C.5).

(3)

In contrast, untreated and placebo-treated animals had high antibody titers and
high BUN, creatinine, ALT, AST, IFN-y, and CIC levels, suggesting immune
complex deposition, a hallmark of AD. This was supported by histopathological
examination of the kidney and liver tissues of the mink.

(4)

Spleen weights of untreated and placebo-treated animals increased by two-fold
compared to treated animals and control mink.

(5)

PCR assay of lymph node tissue demonstrated that virus DNA could be detected
in 83% of the untreated and placebo-treated AD-infected mink, whereas it was
only detected in 18% of drug-treated animals (Fig. C.1).
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Conclusions: Analysis of The Mink Treated with HE2300 and HE2500
(1)

A three times per week dosage regimen of HE2500 and 2300 at 16 ng/k:g dosage
was the most effective means of treating ADV-infected mink; both compounds
appeared to delay the progression of the disease.

(2)

A one time per week regimen of HE2300 failed to protect most mink from lethal
chronic AD.

(3)

The kidneys and liver of vehicle were damaged by immune complex deposition, a
hallmark of AD.

(4)

These findings tend to support the hypothesis that 13-androstene analog treatment
of mink by subcutaneous injection can ameliorate Aleutian disease in mink.

Summary of Conclusion for Both Treatments (TGF-f31
and HE 2300/ 2500)

(1)

DHEA (analogs) and TGF-131 may be able to promote Thl cytokine-type response
that could afford protection for mink from chronic lethal AD.

(2)

TGF-131at 200 and 100 ng/k:g treatment temporarily slowed down the progression
of the disease.

(3)

A three times per week regimen of HE2500 and 2300 was effective in treating
ADV-infected mink; both compounds temporarily halted or slowed down the
progression of the disease.

(4)

These findings support the hypothesis tested in this research that TGF-131
treatment of mink by inguinal vein injection and 13-androstene analog-treatment of
mink by subcutaneously injection can ameliorate Aleutian disease in mink.
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Appendix A. Experimental Methods of Ameliorating Aleutian
Disease in Mink by Treatment with Human rTGF-~ 1

Table Al.
Study Design for TGF-~ 1 treatment of ADV-infected mink.
Treatment Group
Grou121

Grou122

Grou123

Grou124

Mink injected

Mink injected

Mink injected

Mink injected
3 treatmentsa

Treatment

2 weeks
Pre-virus
inoculation

8h
Post-virus
inoculation

2 weeks
Post-virus
inoculation

TGF-~ 1 200 ng/kg

5

5

5

5

20

TGF-~ 1 100 ng/kg

5

5

5

0

15

TGF-~ 1 1 ng/kg

5

5

5

0

15

TGF-~ 1-lnhibitol

5

5

5

0

15

Placeboc

5

5

5

0

15

Total

25

25

25

5

80

Total

a2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation.
bLatency associated peptide, recombinant human (LAPrhTGF-~1 at 500 ng/kg).
cControl; PSS 0.1 % BSA.
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(A)

(B)

(C)

Fig. A.1. These pictures show mink farm.
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(A)

(B)

(C)

Fig. A.2. These pictures depict blood collection method.
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AD Virus Inject
--

-

l
Group 1

Treated with TGF-~ 1injected
2 weeks pre-virus inoclation

Group 2

Treated with TGF-~ 1injected
8 h post-virus inoclation

Group 3

Treated with TGF-~ 1inject d
2 weeks post-virus inoclati n

Group 4

I (TGF-~1 injected 3 times)

Fig. A.3. TGF-~ 1 injection time interval. All animals were injected intraperitoneally (IP)
with a 1: 500 dilution of Aleutian disease virus of mink (strain Utah I) in 0.1 % PSS and
each mink receiving 1ml viral dilution mixture per kilogram body mass.
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(A)

(B)

Fig. A.4. These figures show TGF-~ 1 injection method.
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(A)

(B)

Fig. A.5. These figures depict CEP assay. Runs 1% agarose gel, 55V, 1 hours.
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Appendix B. Tables and figures of Ameliorating Aleutian Disease in Mink by
Treatment with Human rTGF-(3.

Table B.1
Effect of intravenous TGF-~ 1 treatment on survival time of mink with Aleutian disease.

Survivors

Mean Survival Time
(days± SD)

Group No.

Treatment

Group 1

TGF-[31200 ng/kg

3/5*

207 ± 21 *

(treated 2 weeks

TGF-f31100 ng/kg

3/5*

221 ± 26*

pre-virus

TGF-f311 ng/kg

1/5

170 ± 31

inoculation)

TGF-[31-Inhibitor

0/5

116 ± 9**

Placebo

0/5

149± 8

Group 2

TGF-[31200 ng/kg

3/5*

204 ± 9*

(treated 8 h

TGF-[31 100 ng/kg

3/5*

247 ± 17*

post-virus

TGF-[31 I ng/kg
TGF-[31-Inhibitor

1/5

170 ± 38

0/5

123 ± 12

Placebo

0/5

120 ± 25

Group 3

TGF-[31200 ng/kg

2/5

200 ± 33*

(treated 2 weeks

TGF-[31 100 ng/kg

3/5*

223 ± 28**

post-virus

TGF-[31 1 ng/kg

1/5

179 ± 31

inoculation)

TGF-f31-Inhibitor

0/5

135 ± 26

Placebo

0/5

129 ± 24

inoculation)

Group 4

TGF-f31 200 ng/kg

3/5*

248±31**

(3 treatmentsl

Placebo

0/5

133 ± 19

a Animals

a

dying prior to day 266 days
bTGF-[31 was administered 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation.
*p < 0.05 compared to placebo-treated controls.
**p < 0.01 compared to placebo-treated controls.

Table B.2
Effect of intravenous TGF-~

1 treatment

on body weights of mink with Aleutian disease.
Mean Bod}'. Weight (g ± SD)

Treatment

Group 1 (treated 2 weeks
12re-virus inoculation)
Pre-virus Post-virus
b
Exposure Exposure

Group 2 (treated 8 h
12ost-virus inoculation)
Pre-virus Post-virus
Exposure

Exposure

Group 3 (treated 2 weeks
12ost-virus inoculation
Pre-virus Post-virus
Exposure

Exposure

Group4
(3 treatmentst
Pre-virus Post-virus
Exposure
1073 ± 53

Exposure

TGF-B1200 ng/kg

1040 ± 33

828 ± 87*

1035 ± 17 808 ± 65*f

1028 ± 52 788 ± 103*

TGF-B1 100 ng/kg

1040 ± 84

820 ± 114*

1008 ± 38 883 ± 94*

1024 ± 58 853 ± 100*

NDC

TGF-B1 1 ng/kg

1038 ± 48

730 ± 120*

1025 ± 68 765 ± 145

1040 ± 52 655 ± 53*f

NDC

TGF-B1-Inhibitor

1050 ± 67

340 ± 22+

1075 ± 73 373 ± 22*f

1050 ± 53 380 ±

3r

NDC

Placebo

1080 ± 37

339 ± 24+

1025 ± 66 470 ± 60+

1033 ± 43 365 ± 39+

1046 ± 49

969 ± 103*

391 ±41+

aTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation.
bRepresents the last weight available prior to death or sacrifice of the animal.
cND = Not Done
*p ::; 0.05 compared to placebo-treated controls.
+p::; 0.01 compared to pre- vs. post-virus exposure.
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Table B.3
Effect of intravenous TGF-~ 1 treatment on the anti-ADV antibody titers of mink with Aleutian disease.
3
Mean Reciprocal Antibody Titers ± SD

Treatment

Group 1 (treated 2 weeks
pre-virus inoculation)

Group 2 (treated 8 h
post-virus inoculation)

Group 3 (treated 2 weeks
post-virus inoculation

Group 4
(3 treatmentsl

TGF-~ 1 200 ng/kg

358

± 64**

410

± 64**

307 ± 57**

256 ± 29**

TGF-~ 1 100 ng/kg

307

± 57**

218 ± 43**

327 ± 88**

NDC

TGF-~, 1 ng/kg

614

± 150*

563 ± 140**

666 ± 128*

NDC

TGF-~ 1-lnhibitor
Placebo

1126 ± 280
1024 ± 0

1024 ± 0
922 ± 115

922

± 115

1126 ± 280

NDC

1024 ± 132

3

Represents data from the last serum sample taken prior to death or sacrifice of the animal.
bTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation
cND = Not Done
*p ~ 0.05 compared to placebo-treated controls.
**p ~ 0.01 compared to placebo-treated controls.
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Table B.4
Effect of intravenous TGF-~ 1 treatment on blood urea nitrogen (BUN) levels in mink with Aleutian disease.
Mean BUN levels (mgldL ± SD)
Group 4
(3 treatmentst
Pre-virus Post-virus
Exeosure Exeosure

Group 2 (treated 8 h
2ost-virus inoculation)
Post-virus
Pre-virus
Exeosure
Exeosure

Group 3 (treated 2 weeks
2ost-virus inoculation
Pre-virus
Post-virus
Exeosure
Exeosure

TGF-~ 1 200 ng/kg 6.21 ± 1.23 17.86 ± 4.90*

6.83 ± 3.68 23.10 ± 5.20*

8.30 ± 2.46 22.77 ± 4.47*

TGF-~ 1 100 ng/kg 5.15 ± 1.29 14.14 ± 3.51*

7.98 ± 1.66 15.25 ± 3.40*

8.07 ± 1.23 15.08 ± 6.96*

NDC

Treatment

Group 1 (treated 2 weeks
2re-virus inoculation)
Post-virus
Pre-virus
Exposureb
Exeosure

7.57± 2.41 10.42 ± 2.73*

TGF-~ 1 1 ng/kg

5.46 ± 2.38 31.32 ± 6.96*t"

6.75 ± 1.76 33.15 ± 11.84

8.54 ± 2.54 29.15 ± 8.15*

NDC

TGF-~ 1-Inhibitor

7.08 ± 1.23 84.07 ±17.43+

7 .53 ± 1.45 73.15 ± 18.3+

5.39 ± 1.69 61.81 ± 15.74+

NDC

Placebo

5.48 ± 2.02 63.83 ± 12.68+

5.29 ± 1.64 56.59 ± 9.20+

7.70 ± 1.98 67.55 ± 5.03+

aTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation
bRepresents data from the last serum sample taken prior to death or sacrifice of the animal.
cND = Not Done
*p ::; 0.05 compared to placebo-treated controls.
+p::; 0.05 compared to pre- vs. post-virus exposure.

6.16± 1.88 62.66 ± 8.98+
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Table B.5
Effect of intravenous TGF-~ 1 treatment on serum interferon gamma (IFN-y) levels in mink with Aleutian disease.

± SD)
Mean lnterferon-y levels (l::!:M

Treatment

Group 1 (treated 2 weeks
2re-virus inoculation)
Post-virus
Pre-virus
Exposure b
Exposure

Group 2
2ost-virus
Pre-virus
Exposure

(treated 8 h
inoculation)
Post-virus
Exposure

Group 3 (treated 2 weeks
2ost-virus inoculation
Post-virus
Pre-virus
Exposure
Exposure

Group 4
(3 treatmentst
Pre-virus Post-virus
Exposure Exposure

TGF-~ 1 200 ng/kg 6.36 ± 0.86

18.13 ± 3.31*t"

7.08 ± 1.06 15.48 ± 5.60*

6.76 ± 2.76 16.63 ± 2.42*f

TGF-~ 1 100 ng/kg 5.86±1.10

11.97 ± l.74*f

7.26 ± 1.71 17.60 ± 4.90*f

8.01 ± 2.20 16.89 ± 3.60*f

NDC

23.90 ± 8.76+

NDC

TGF-~ 1 1 ng/kg

5.64 ± 0.84 24.99 ±4.20+

6.25 ± 1.84 25.03 ± 5.32*f

7.06±2.16

TGF-~ 1-Inhibitor

5.41 ± 0.96 40.93 ± 6.99+

6.81 ± 1.85 39.83 ± 6.22+

6.22 ± 1.60 50.41 ± 10.99+

Placebo

6.05 ± 1.51 31.60 ± 2.81+

5.81 ± 1.27 37.29 ± 4.24+

6.65 ± 1.81 42.00 ± 11.26+

6.18 ± 1.77 15.96 ± 4.81 *

NDC
6.19 ± 1.53 36.96 ± 6.10+

aTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation
bRepresents data from the last serum sample taken prior to death or sacrifice of the animal.
cND = Not Done
*p ~ 0.05 compared to placebo-treated controls.
+p ~ 0.05 compared to pre- vs. post-virus exposure.
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Table B.6
Effect of intravenous TGF-~ 1 treatment on average of serum TGF-~ 1 levels in mink.

Mean TGF-~ 1 levels (ng/ml
Group 1 (treated 2 weeks
2re-virus inoculation)

Group 2 (treated 8 h
2ost-virus inoculation)
Baseline
levels

± SDl

Group 3 (treated 2 weeks
2ost-virus inocul<!tion
Baseline
levels

Group 4
(3 treatments)b
Baseline
levels

Treatment

Baseline
levels

TGF-~ 1 200 ng/kg

1.08

0.95

± 0.07*

0.78

0.88 ± 0.11 *

0.79

0.84 ± 0.11 *

TGF-~ 1 100 ng/kg

1.02

0.91

± 0.06*

0.78

0.88 ± 0.07*

0.77

0.84

± 0.06*

NDC

TGF-~ 1 1 ng/kg

0.82

0.77 ± 0.02

0.78

0.77 ± 0.03

0.79

0.77

± 0.03

NDC

TGF-~ 1-lnhibitor

0.58

0.55

± 0.07*

0.78

0.67

± 0.03

0.80

0.62

± 0.11 *

NDC

Placebo

0.87

0.73

± 0.05

0.80

0.73 ± 0.04

0.77

0.74

± 0.02

Ave.

Ave.

Ave.

1.06

1.06

Ave.
1.07 ± 0.26*

0.73

± 0.04

aMean levels after death or at sacrifice.
bTGF-~ 1 was administered sequentially at 2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation.
cND = Not Done
*p ::;;0.05 compared to placebo-treated controls.
......
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Table B.7
Effect of intravenous TGF-~ 1 treatment on serum TGF-~ 1 levels in mink.
Mean TGF-@1 levels (ng/ml ± SD)
Time months virus ex2osure
4
3
5

Group No.

Treatment

Pre-virus
Exposure

8h

1

2

Group 1

TGF-[3 1 200 ng/kg

1.08±0.16

1.04±0.10

0.98±0.03

0.95±0.08

0.95±0.07

0.91±0.06 0.91±0.10 0.93±0.03 0.83±0.00 0.92±0.00

(2 weeks

TGF-[31 100 ng/kg

1.02±0.11

1.02±0.11

0.92±0.01

0.92±0.05

0.90±0.04

0.88±0.03 0.91±0.04 0.89±0.09 0.85±0.03 0.85±0.03

pre-virus

TGF-[3 1 1 ng/kg

0.82±0.08

0.79±0.08

0.78±0.07

0.78±0.10

0.76±0.08

inoculation)

TGF-[31-lnhibitor

058t0,05

0.54±0.21

0>81±0.08

0.70±0.08

0.57±0.10
0.75±0.09

0.51±0.03

Placebo

0.55±0.08
0.78±0.08

0.77±0.05 0.77±0.09 0.77±0.04 0.74±0.08 0.76±0.07
a
0.52±0.00
0.72±0.04 0.64±0.00

Group 2

TGF-[31 200 ng/kg

0.79±0.08

TGF-[3 1 100 ng/kg

0.78±0.06

0.93±0.07
0.91±0.10

0.87±0.10

(8 h post-

1.00±0.04
--~ffi
.,;,
0.97±0.10
r 0±011

virus

TGF-[3 1 1 ng/kg

0.78±0.05

obJi~90.78±0.07

0.76±0.06

0.81±0.05

inoculation)

TGF-[31-Inhibitor

0.78±0.05

0'.69\0:O9
,,,n.'1ft : -,

0.68±0.07

0.66±0.06

0.61±0.05

0.80±0.09 • o:1<£~fo9·

0.73±0.04

0.68±0.02

0.72±0.0 5

--

Placebo

It™

0.73±0.05

0.89±0.12

6

7

8

0.83±0.09 0.85±0.03 0.82±0.06 0.75±0.00
0.91±0.09 0.86±0.10 0.78±0.06 0.84±0.02 0.82±0.07
0.82±0.05 0.79±0.06 0.74±0.06 0.72±0.03 0.75±0.06
0.62±0.05 0.69±0.06 0.64±0.06
0.67±0.00

Group 3

TGF-[31 200 ng/kg

0.79±0.09

0.78±0.09

1.07±0.10

0.97±0.12

0.91±0.11

(2 weeks

TGF-[3 1 100 ng/kg

0.77±0.05

0.75±0.05

0.~5±0:13

0.89±0.13

0.88±0.10

0.84±0.11 0.79±0.05 0.77±0.07 0.76±0.10 0.72±0.01
0.85±0.01 0.83±0.03 0.81±0.04 0.84±0.06 0.83±0.06

post-virus

TGF-[3 1 1 ng/kg

0.79±0.03

0.77±0.03

0.82±0,03

0.77±0.07

0.75±0.02

0.77±0.12 0.75±0.09 0.75±0.03 0.73±0.01 0.76±0.00

inoculation)

TGF-[31-Inhibitor

0.80±0.05

0.77±0.04

0.56±0.08

0.54±0.10

0.53±0.06

Placebo

0.77±0.05

0.74±0.08
::. iv.

0.75±0:06

0.66±0.07

0.62±0.06

0.56±0.03 0.61±0.03
0.66±0.08 0.62±0.03

1.3slo:o8

1.59£0:17

1.27±0.11

1.04±0.05

0.96±0.11 0.86±0.07 0.84±0.01 0.87±0.01 0.81±0.04

~

Group 4b TGF-[31 200 ng/kg
3 treatment

1.06±0.10

,..,,

aAnimal was already dead prior to this sampling time.
b2 weeks pre-, 8 h post-, and 2 weeks post-virus inoculation.
The gray region represents the treated (TGF-~ 1) and untreated (inhibitor, placebo) injected.
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(C)

(D)

Fig. B.l. Detection of ADV DNA in mink treated with TGF-~ 1• The expected fragment size was 379 base pairs, representing
nucleotides 224-602. Group 1: treated with TGF-~ 1 injected 2 weeks pre- (A), Group 2: 8 hours post- (B), Group 3: 2 weeks aftervirus inoculation (C), and Group 4: TGF-~ 1 injected 3 times (2 weeks pre-, 8 h post-, and 2 weeks post- virus inoculation) (D).
Lane 1-5: TGF-~ 1 at 200 ng/kg, 6-10: 100 ng/kg, 11-15: 1 ng/kg, 16-20: rhLAPTGF-~ 1 at 500ng/kg (inhibitor) and 21-25: PSS in
0.1 % BSA. +: positive control (379 base pairs) , -: negative control and ST: 100kb DNA ladder. PCR assay of lymph node tissue
confirmed that untreated mink had significant levels of virus whereas TGF-~ 1 treated mink had none.
,_.

-+>,.
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Appendix C. Tables and figure of Effects of HE2300 and
HE2500 on the Outcome of Aleutian Disease in Mink

Table C.1.
Study Design for DHEA treatment of ADV-infected mink.

Treatment

Received Compound

Number of
animals

Infected, HE2500a

16 ng/kg, 3 times per week received

5

Infected, HE2300b

16 ng/kg, one times per week received

5

Infected, HE2300

16 ng/kg, 3 times per week received

17

Infected, Vehiclec

16 ng/kg, 3 times per week received

17

Infected, untreated

Virus with untreated

6

Normal Control

No virus, untreated

5

Total

55

aFluasterone (FLST); 16a-fluoro-5-androsten-17-one; synthetic androstene derivative.
b~-androstenetriol (~-ABT); 5-androstene-3~-7~-triol; natural androsten hormone.

Table C.2.
Effects of subcutaneous HE2500 and HE2300 treatment on survival time of ADV-infected mink.

Treatment Group

Survivors

Survivors
(Adjusteda)

HE2500b 3X/wk

3/5

3/4

5.8 ± 3.2

7.0± 2.0

HE2300c lX/wk

1/5*

1/5*

4.0 ± 2.4**

4.0 ± 4.0**

HE2300 3X/wk

9/17

9/17

5.7 ± 2.6

5.7 ± 2.6

Vehicle 3X/wk

1/17*

1/14*

4.0 ± 2.2**

4.5 ± 2.5**

Untreated

0/6*

0/6*

3.8 ± 1.5**

3.8 ± 1.5**

Normal Control

5/5

5/5

8.0±0

8.0± 0

Mean Time to Death
(months± SD)

Mean Time to Death
(months ± SD; Adjusteda)

alncludes only those animals that demonstrated pathology attributable to Aleutian disease.
bFluasterone (FLST); 16a-fluoro-5-androsten-17-one; synthetic androstene derivative
c B-androstenetriol (B-AET); 5-androstene-3B-7B-triol; natural androsten hormone.
*p < 0.001 compared to normal control animals.
**p = 0.016 compared to normal control animals.

.....

~
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Table C.3
Effects of subcutaneous HE2500 and HE2300 treatment on serum ion levels in ADV-infected mink.

Na+(mmol/L±

SD)

Ca +z(mg/dL ± SD)

K+ (mmol/L± SD )

er (mmol/L

± SD )

Treatment Group

PreExposure

After Virus
Exposurea

PreExposure

After Virus
Exposure"

PreExposure

After Virus
Exposurea

PreExposure

After Virus
Exposurea

HE2500b 3X/wk

148 ± 5.6

143 ± 5.1

10.2 ± 0.9

9.7 ± 1.88

6.4 ± 0.5

4.9 ± 0.9

116 ± 6.2

108 ± 5.4

HE2300c IX/wk

151 ± 4.8

144 ± 5.0

10.1 ± 0.9

10.1 ± 1.3

6.1 ± 0.6

4.9 ± 0.8

116 ± 4.8

108 ± 5.5

HE2300 3X/wk

149 ± 4.6

144 ± 3.7

10.0 ± 0.5

10.0 ± 1.0

6.1 ± 0.9

4.9 ± 0.8

118 ± 4.9

111±5.2

Vehicle 3X/wk

145 ± 4.7

161 ± 4.2

10.1 ± 0.8

7.o ± L3*r

7.9 ± 0.8

7.1 ± 0.9*

117±5.5

130 ± 5.3*

Untreated

150±2.1

166 ± 4.3

10.4 ± 0.4

8.2 ± 2.7

7.6 ± 0.7

6.7 ± 0.8*

121 ± 7.1

132 ± 6.8*

Normal control

149 ± 3.0

146 ± 5.1

9.9 ± 0.9

10.0 ± 0.9

5.0 ± 0.5

4.9 ± 0.3

113 ± 7.3

106 ± 9.6

aRepresents the last serum available prior to death or sacrifice of the animal.
synthetic androstene derivative).
bFluasterone (FLST; 16a-fluoro-5-androsten-17-one;
c~-androstenetriol (~-AET; 5-androstene-3~-7~-triol; natural androsten hormone).
*p < 0.05 compared to normal control animals.
+p < 0.05 compared to pre- vs. post-virus exposure.

-
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Table C.4
Effects of subcutaneous HE2500 and HE2300 treatment on serum liver enzyme levels of ADV-infected mink.

Alanine Aminotransferase(U/L

± SD)

Aspartate Aminotransferase (U/L ± SD)

Treatment Group
Pre-Exposure

After Virus Exposurea

Pre-Exposure

After Virus Exposurea

± 10.21 *

HE2500b 3X/wk

40

± 8.47

65 ± 17.14

54

± 9.13

HE2300c lX/wk

33

± 4.97

101 ± 26.22*f

52

± 12.24

102 ± 17.26*f

HE2300 3X/wk

34

± 7.54

79 ± 33.34+

49

± 36.7

80 ± 19.56*

Vehicle 3X/wk

40

± 11.13

194 ± 85.73*f

Untreated

43

± 9.63

220

Normal control

41

± 4.44

42

62 ± 38.74

± 36.0

± l 19.4*f

58

± 2.13

39 ± 6.02

74

132 ± 68.53*f
174 ± 50.60*f
42

± 2.13

aRepresents the last serum available prior to death or sacrifice of the animal.
bFluasterone (FLST; 16a-fluoro-5-androsten- l 7-one; synthetic androstene derivative).
cf3-androstenetriol (f3-AET; 5-androstene-3 f3-7f3-triol; natural androsten hormone).
*p < 0.05 compared to normal control animals.
+p < 0.05 compared to pre- vs. post-virus exposure.

-UI

Table C.5
Effects of subcutaneous HE2500 and HE2300 treatment on serum levels of blood urea nitrogen and creatinine in ADV-infected
mink.

Blood Urea Nitrogen (mg/dl

± SD)

Creatinine (mg/dl

± SD)

After Virus Exposurea

Treatment Group

Pre-Exposure

After Virus Exposurea

Pre-Exposure

HE2500b 3X/wk

22 ± 5.07

22 ± 4.38

1.3 ± 0.2

0.9 ± 0.18

HE2300c lX/wk

24.8

± 6.50

26.7 ± 4.99*

1.6 ± 1.5

1.4 ± 0.36*

HE2300 3X/wk

23.8

± 6.02

25.8 ± 5.83

1.2 ± 0.7

1.1 ± 0.29

Vehicle 3X/wk

27.7

± 10.61

34.5

± 15.37*

1.4 ± 0.4

2.4 ± 1.01*r

Untreated

25.5

± 10.68

40.8

± 12.02*r

0.5 ± 0.5

3.1 ± 1.28*r

0.9 ± 0.2

0.7

Normal control

15.0 ± 9.4

14.4 ± 4.53

± 0.11

aRepresents the last serum available prior to death or sacrifice of the animal.
bFluasterone (FLST; 16a-fluoro-5-androsten-17-one; synthetic androstene derivative).
c~-androstenetriol (~-AET; 5-androstene-3~-7~-triol; natural androsten hormone).
*p < 0.05 compared to normal control animals.
+p < 0.05 compared to pre- vs. post-virus inoculation.

-
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(A)

(B)

(C)

Fig. C. 1. Detection of ADV DNA in mink treated with HE2300 and HE2500. (A) Lane 15: Infected/HERF 2300 lx/wk, 6-10: lnfected/HERF 2500 lx/wk, (B) Lane 45-50:
Infected/untreated, 51-55: Normal control, (C) Lane 11-27: Infected/HERF 2300 3/week
and (D) Lane 28-44: Infected/vehicle 3x/wk. S: DNA ladder lO0bp, +: AD positive
control and-: AD negative control.
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